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Abstract 
Patient-, Provider- and System-Level Factors Impacting Contraceptive Access and Use 
Colleen Patricia Judge-Golden, PhD 
University of Pittsburgh, 2019 
Contraception plays vital roles in promoting women’s health, quality of life and 
reproductive autonomy. The research described in this dissertation aimed to identify and evaluate 
factors at the patient, provider, and system levels that contribute to individuals’ abilities to access 
and use contraceptive methods in concordance with their goals and preferences. We assessed 
contraceptive preference matching and evaluated system-level policies and provider practices that 
directly impact access to specific methods, with a particular focus on the medically vulnerable 
population of women Veterans who use the Veterans Affairs (VA) healthcare system. 
First, we used a novel measure to investigate the extent to which women Veterans are 
currently using the contraceptive methods they consider to be “ideal,” and identified characteristics 
associated with ideal-current method match. Only 58% were currently using their stated ideal 
method, and match was reduced among non-white women and women with mental health 
disorders, suggestive of established health care disparities. However, qualitative analysis revealed 
that the bulk of reasons for ideal method non-use were personal and contextual, rather than 
resulting from access barriers. Our results underscore the complexity of contraceptive method 
selection and highlight enduring methodologic challenges of measuring contraceptive preferences. 
Next, we used decision analysis to estimate financial and reproductive health impacts to 
the VA healthcare system of a policy change to allow for twelve-month dispensing of oral 
contraceptive pills. We found that extended dispensing would better enable women Veterans to 
v 
prevent unintended pregnancies, while also being economically feasible and sustainable for VA. 
These findings may help to inform evidence-based policy in VA. 
Finally, we conducted a cross-sectional survey study to evaluate provider-level adherence 
to best practice guidelines for provision of long-acting reversible contraception (LARC, i.e. 
intrauterine devices and contraceptive implants) in a single large healthcare system in Western 
Pennsylvania. We found substantial room for improvement in adherence to best practices, 
particularly same-day provision of these methods, and identified provider-reported barriers to best 
practice implementation, which were primarily logistical rather than stemming from knowledge 
deficits. These results may be used to inform efforts to expand access to LARC methods across 
this healthcare system.  
vi 
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1.0 Introduction 
1.1 Contraceptive methods and US epidemiology 
Contraceptive methods comprise a variety of practices, medications and devices used to 
prevent pregnancy. These methods vary in their effectiveness at preventing pregnancy (Table 1), 
mechanisms of action, and frequency and timing of use.1 In the United States, greater than 99% of 
heterosexually experienced women have ever used any contraceptive method, and 88% have used 
a moderately or highly effective, reversible method.2 The distribution of contraceptive methods 
used by US women is shown in Figure 1. Female sterilization and oral contraceptive pills (OCPs) 
have remained the two most common contraceptive methods for decades.2,3 Notably, the 
proportion of women using long-acting reversible contraceptive methods (LARC), including 
intrauterine devices (IUDs) and contraceptive implants, has increased dramatically in recent years, 
from 6.0% of contraceptive users in 2008 to 14.3% in 2014, while proportions of women relying 
on male and female sterilization have decreased over the same timeframe.3 
 
Table 1 Contraceptive methods by effectiveness 
HIGHLY 
EFFECTIVE a 
Typical-use failure 
rate <1% b 
MODERATELY 
EFFECTIVE a 
Typical-use failure 
rate 4-7% b 
LEAST  
EFFECTIVE 
Typical use failure 
rate 13-21% b 
NO 
METHOD 
Pregnancy 
rate ~85% 
Female sterilization 
Male sterilization 
Intrauterine device 
Subdermal implant 
Contraceptive pills 
Transdermal patch 
Vaginal ring 
Medroxyprogesterone 
injections 
Male condom 
Female condom 
Withdrawal 
Spermicides 
Diaphragm a 
Cervical cap a 
Sponge 
Fertility awareness 
 
a Requires a prescription or procedure for use. 
b Indicates the percentage of women experiencing a pregnancy during the first year of typical use.1 
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Figure 1 Contraceptive methods used by US women ages 15-44, 2014 
Data are from the National Survey of Family Growth 2013-2015 female respondent files, as reported in Kavanaugh 
and Jerman, 2018.3 Current method use is defined as use of a method within the past month, and is categorized 
according to the most effective method use, as participants could report use of more than one method.  
Methods are listed according to effectiveness category: blue = highly effective methods; red = moderately effective 
methods; grey = least effective methods.  
a Other methods include diaphragm, sponge, and spermicides. 
b Other hormonal methods include patch, ring and injectables. 
 
1.2 Contraception, health and human rights 
Use of contraception allows women to prevent undesired pregnancies and to space their 
pregnancies in order to optimize maternal and neonatal health.4,5 In addition to preventing 
pregnancy, contraceptive methods contribute to health and quality of life in a variety of ways. For 
example, hormonal methods are used to treat conditions such as menstrual disorders, acne, and 
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endometriosis, and their use is associated with reduced risks of endometrial, ovarian, and 
colorectal cancer.6 Due to the numerous health-related benefits of contraceptive use, contraceptive 
counseling and provision are broadly recognized as essential preventive health services for women 
of reproductive age.7  
Contraception also plays an essential role in guaranteeing reproductive autonomy, and the 
ability to delay and time pregnancies has had profound implications for the social and economic 
advancement of women worldwide.8 Reproductive autonomy was affirmed as the basic human 
right of individuals “to decide freely… the number, spacing and timing of their children” at the 
International Conference on Population and Development in Cairo, Egypt in 1994.9 The 
Reproductive Justice movement, which was founded by Black women in the US shortly before 
this convening, more broadly envisions reproductive rights in the context of social justice, 
including the right to “maintain personal bodily autonomy, have children, not have children, and 
parent the children we have in safe and sustainable communities.”10 Equitable access to acceptable 
contraceptive methods is one necessary, though not sufficient, piece of this bold vision. 
1.3 Contraception and unintended pregnancy 
Consistent use of effective contraception dramatically reduces the risk of unintended 
pregnancy, defined as pregnancies occurring sooner than desired or when no future children were 
desired.11 Indeed, non-use or inconsistent use of contraception accounts for 95% of unintended 
pregnancies, with only 5% resulting from true contraceptive failure.12 Unintended pregnancies 
comprise nearly half of all pregnancies in the United States each year,13 a figure which has 
remained high over decades of measurement despite extensive public health programming aimed 
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at reducing unplanned childbearing.14,15 Importantly, the highest rates of unintended pregnancy 
continue to be observed among non-white and low-income women, and those with lower 
educational attainment.13,14 
The high rate of unintended pregnancy in the US is widely regarded as a public health crisis 
due to associations of unintended pregnancy with adverse health behaviors and outcomes, 
including delayed or inadequate prenatal care, increased substance use during pregnancy, and pre-
term birth.16,17 The strength of these associations has come under increasing scrutiny in recent 
years, largely because the observational studies necessary for studying human fertility are unable 
to fully untangle the effects of pregnancy intention from potent confounders such as 
socioeconomic status, age, and race/ethnicity, which are independently associated with both health 
outcomes and risk of unintended pregnancy.17,18 There is also increasing recognition of the 
scientific and conceptual limitations of measures of pregnancy intention, including their 
retrospective nature, inability to account for emotional aspects of pregnancy and childbearing, and 
the non-universality of planning- and timing-based reproductive paradigms.19-22 Nevertheless, the 
reduction of unintended pregnancy is a longstanding public health goal, and largely drives policy 
efforts to improve access to contraception.7,23 
The unilateral focus of contraceptive policies and public health programs on reducing 
unintended pregnancy has led to efforts to measure contraceptive access by evaluating uptake of 
the most highly effective methods, such as IUDs and implants.24 Recent declines in the rate of 
unintended pregnancy, from 51% in 2008 to 45% in 2011, have indeed been attributed in part to 
increasing use of highly effective contraceptive methods.13,25 However, the assumption that 
optimizing contraceptive access automatically leads to use of more effective contraception by 
more people ignores the multifaceted reasons that individuals use contraceptive methods and 
threatens to devalue the primacy of individual preferences and autonomy.26,27 Although efficacy 
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at preventing pregnancy is important to the majority of women in selecting a contraceptive 
method,28,29 other characteristics are highly influential in women’s decisions to seek and use 
contraception, including frequency of use, side effect profiles and non-contraceptive benefits.29-31 
The perceived importance of avoiding pregnancy while using contraception is also not 
universal,32,33 and many women express uncertain pregnancy intentions or ambivalence about 
avoiding or achieving pregnancy.34-36 The clarity and strength of these intentions fluctuate over 
time and may predict the likelihood of consistent contraceptive use.32,34,36-38  
Moreover, initiatives that focus solely on prevention of unintended pregnancy through 
uptake of highly effective methods can exacerbate societal stigmas and promote coercion, 
particularly of individuals belonging to socially marginalized groups.27,39 There is a significant 
history of reproductive injustices inflicted upon people of color and low-income individuals in the 
US by health care providers and the government in the name of eugenics and in the service of 
misguided poverty alleviation strategies. This includes coercive sterilization programs targeting 
poor women and women of color, and policy proposals conditioning welfare benefits on 
contraceptive implant provision.39,40 There is also ongoing potential for coercion and bias in 
contraceptive counseling according to sociodemographic characteristics.41-43 In light of these 
injustices, family planning providers, researchers and policy makers have a responsibility to ensure 
that promotion of public health goals does not overshadow individual preferences and autonomy, 
particularly among vulnerable populations.  
The limitations and potential harms of measures of unintended pregnancy and 
contraceptive efficacy have led to calls by reproductive justice advocates and family planning 
researchers to develop new frameworks and instruments that more accurately measure access to 
contraceptive methods, quality of contraceptive counseling, or meeting of patient 
preferences.21,22,26,27 The research described in this dissertation, which assesses contraceptive 
 6 
preference matching and evaluates policies and practices impacting access to specific methods, 
strives to acknowledge the multifaceted contribution of contraception to health, quality of life and 
self-determination, in addition to its efficacy in preventing unintended pregnancy. 
1.4 Contraceptive access and disparities 
Differences in contraceptive use are observed among US women according to demographic 
characteristics, with non-white women and women of lower socioeconomic status being less likely 
to use any contraception or highly effective methods.44-47 These differences are understood as 
disparities due to the corresponding higher rates of unintended pregnancy among these same 
populations.13 The types of contraceptive methods that women select and use also vary according 
to race/ethnicity, socioeconomic status and educational attainment.3,44,47 For example, non-
Hispanic Black and lower-income women have historically been more likely to rely on female 
sterilization and barrier methods for contraception, whereas use of the pill and other hormonal 
methods is more common among white women and women with higher educational 
attainment.44,48,49 Of note, longstanding differences in use of female sterilization appear to have 
decreased in the most recently available national data, with reductions driven by reduced use by 
low income and Black women, and are no longer statistically significant across race/ethnicity.3,44 
The reasons for disparities in contraceptive use are complex, and include factors operating 
at the patient, provider, and healthcare system levels.50 At the patient level, preferences for 
contraceptive method features are highly influential to women’s decisions about contraception, 
and vary broadly. These include preferences about the use of synthetic hormones,29,30 acceptability 
of a foreign object in the body, as with LARC methods,51 the impact of methods on sexual 
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satisfaction,51,52 the desirability of menstrual control or amenorrhea as compared to a “natural” 
menstrual cycle,31,51,53,54 and the need for a method that can’t be detected by an intimate partner.55 
Religious and cultural attitudes toward contraception and pregnancy may also influence 
contraceptive use and method selection,53,56 as does the perceived importance of avoiding 
pregnancy at a given time.32-34  
Importantly, preferences for method features have been found to vary across 
sociodemographic characteristics. For example, studies have found that non-white women are 
more likely than white women to prefer non-hormonal methods and methods that protect against 
sexually transmitted diseases, and may be less likely to consider method effectiveness as extremely 
important.30,54 Emerging evidence suggests that women of minority race/ethnicity may also have 
stronger preferences for control over method discontinuation, and for methods that promise an 
immediate return to fertility.54 Knowledge about contraceptive methods also informs method 
selection and use,57 and disparities have been noted, with racial/ethnic minority women having 
reduced awareness of available methods and more limited knowledge about their safety and 
efficacy.58-60 Correcting disparities in knowledge is essential to ensure that women can make 
informed decisions. However, contraceptive method provision is unique within medical care in 
that there is not a “correct” method for any given woman, and the close relationship of 
contraception with sexuality, intimate relationships and reproductive desires makes contraceptive 
method selection particularly preference-sensitive.26 
Interactions with health care providers are necessary to obtain the most highly effective 
contraceptive methods, which require prescriptions or procedures for use (Table 1). Providers 
influence the contraceptive methods that women have access to and select in a variety of ways, 
including their knowledge and expertise,61,62 counseling styles,63 and practices related to method 
provision.64-66 Providers may also exhibit biases with regards to particular methods or patient 
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sociodemographic characteristics. For instance, women from socially marginalized groups have 
reported feeling pressured to choose highly effective methods and that providers neglect their 
preferences in counseling.43,67 When studied empirically, providers have been found to be more 
likely to recommend IUDs to women who were non-white and low-income.41 Counseling 
strategies that operate under the assumption that efficacy is the most important feature or that focus 
on specific method promotion, such as “LARC First” initiatives, may reinforce or exacerbate 
stigmas and contribute to coercion.27 In contrast, counseling strategies that are intentionally 
patient-centered and emphasize shared decision-making are associated with increased satisfaction 
with chosen contraceptive methods and with family planning care.63 
Factors operating at the system level influence the broader context of contraceptive access 
and availability. For instance, costs of contraceptive methods and insurance coverage have been 
shown to influence method selection and continuation,68 and research suggests that women are 
more likely to select methods with high upfront costs, such as IUDs and implants, when those costs 
are mitigated or removed.69,70 Insured US women have seen significant reductions in out-of-pocket 
costs for contraception in recent years owing to provisions of the Affordable Care Act which 
mandate coverage of the full range of prescription contraceptive methods with zero cost 
sharing.71,72 Concurrent expansion of Medicaid eligibility criteria and launch of the insurance 
marketplace led to a nearly 40% reduction in the number of uninsured women of reproductive age 
between 2012 and 2015.73 Other system-level factors that impact contraceptive use include 
contraceptive method stocking and availability, and medication dispensing limits. As with other 
medications, dispensing of short-acting hormonal contraceptive methods (i.e. the pill, patch and 
ring) is typically capped at 30-, 60-, or 90-day supplies by most US insurers.74 However, 
dispensing greater initial quantities of  hormonal contraception is associated with improved 
continuation of those methods, fewer gaps in coverage, and reductions in unintended 
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pregnancies.75,76 These data have led to state-level legislative efforts to mandate insurance 
coverage for 12-month contraceptive supplies dispensed at an initial fill.74 
1.5 Women Veterans and contraception 
Two projects in this dissertation focus on the population of women Veterans who use the 
Veterans Affairs (VA) healthcare system. Like women in the general population, women Veterans 
need access to contraception. The number of women Veterans using VA for health care has 
increased nearly 3-fold since the turn of the century, to almost half a million women in fiscal year 
(FY) 2015, of whom over 40% are of reproductive age (18-44 years old).77 This demographic shift 
has propelled a growing commitment by VA to provide high-quality, comprehensive care to 
women Veterans.78,79 Initiatives have included the development of comprehensive women’s health 
clinics, and mandating that female VA patients have access to a primary care provider trained in 
gender-specific competencies, including contraceptive counseling and provision.79 
Women Veterans who use VA for health care (~22% of all woman Veterans) comprise a 
unique and vulnerable population, with a high burden of chronic medical conditions and mental 
health disorders compared to women in the general US population,77,80,81 as well as high rates of 
sexual trauma and adverse psychosocial factors including homelessness.82,83 These characteristics 
may render this population particularly vulnerable to pregnancy-related morbidity, and to the 
potential negative consequences associated with unintended pregnancy.17 This population is also 
disproportionately comprised of women of minority race/ethnicity (42% in FY2015),77 who in the 
US population experience both higher rates of unintended pregnancy,13 as well as dramatically 
higher risks of maternal and neonatal morbidity and mortality.84,85 The unique demographics of 
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this population underscore the importance of contraceptive access in ensuring the health and well-
being of women Veterans. 
VA offers the full range of contraceptive methods approved by the US Food and Drug 
Administration (FDA), including short-acting hormonal methods and LARC, as well as 
sterilization procedures. These methods are available to Veterans at low or no cost through a 
centralized pharmacy and device formulary.86,87 Importantly, contraceptive methods obtained 
through VA are not exempt from copayments, as they are for the majority of insured US women 
under the Affordable Care Act.72 Instead, a Veteran’s copayment status is determined by a 
combination of factors such as income and level of service-connected disability, defined as “injury 
or illness that was incurred or aggravated during active military service.”88,89 Individuals who are 
not exempt from copayments also incur copayments for contraceptive medications; in 2019 this is 
a flat fee of $8 for a 30-day supply.86 While primary care providers are expected to provide 
counseling and prescribe the bulk of contraception, VA gynecologists are available for more 
complex cases and for LARC insertion procedures. However, the availability of onsite gynecology 
is known to vary between care sites and is associated with onsite LARC availability.90 Other 
structural factors are also associated with availability and use of prescription contraception, such 
as being seen in a hospital-based versus community-based clinic, or in a designated women’s 
health clinic versus other primary care setting.91,92  
Until recently, little has been known about contraceptive use and unintended pregnancy 
among women Veterans. The Examining Contraceptive Use and Unmet Need among Women 
Veterans (ECUUN) study sought to fill this gap by surveying a nationally representative sample 
of 2,300 reproductive-aged women Veterans who use VA for primary care.93 Women completed 
computer-assisted telephone interviews assessing their pregnancy histories, use of contraception, 
and experiences seeking reproductive health care in VA. Data from ECCUN indicate that overall 
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contraceptive use and unmet need for prescription contraception are similar among women 
Veterans who use VA compared to women in the general US population, although greater 
proportions of women Veterans use LARC methods and fewer use female sterilization compared 
to US women.93 This population also reports a similarly high proportion of unintended 
pregnancies, and seeks abortion at similar rates as US women.93,94 Notably, differences and 
potential disparities have been noted in contraceptive use, preferences and knowledge among 
vulnerable populations of women Veterans, including women of minority race/ethnicity,30,95,96 
women with chronic medical conditions,97 and women with mental health disorders.98,99 Increased 
understanding of factors impacting contraceptive access and use in this population is necessary to 
improve contraceptive care for women Veterans. 
1.6 Goals of dissertation 
The research described in this dissertation aims to evaluate patient-, provider-, and system-
levels factors which may influence individuals’ abilities to obtain and use contraception in 
concordance with their goals and preferences.  
In the first paper, we investigate the extent to which women Veterans are using the 
contraceptive methods they consider to be “ideal,” and identify characteristics associated with 
ideal-current method match, a novel measure designed to evaluate contraceptive access while 
centering patient preferences. We also qualitatively analyze women’s open-ended reasons for non-
use of their stated ideal method.  
In the second paper, we use decision analysis to estimate the impact of twelve-month oral 
contraceptive pill dispensing on VA health system costs and women Veteran’s efforts to prevent 
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unintended pregnancies. This work aims to translate existing research data to a real-world setting 
in order to inform evidence-based, system-level policy to improve contraceptive access for women 
Veterans using the pill.  
Finally, in the third paper, we describe results from a cross-sectional survey study 
evaluating provider-level adherence to best practice guidelines for LARC provision in a single 
large healthcare system. By characterizing current practices and eliciting provider-identified 
barriers to same-day LARC provision, this work aims to inform efforts to expand access to LARC 
methods across this system. 
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2.0 Agreement Between Self-Reported “Ideal” and Currently Used Contraceptive Methods 
Among Women Veterans in the ECUUN Study  
2.1 Introduction 
The efficacy of contraceptive methods in preventing pregnancy is an important 
consideration for the majority of women;28-30 however, additional factors are highly influential to 
decisions about contraceptive use and method type, including the perceived importance of 
avoiding pregnancy;38 emotional orientations toward pregnancy;100,101 personal and cultural 
attitudes toward pregnancy and birth control;53,102 and preferences for method characteristics such 
as frequency of use, sexual satisfaction, and side effect profiles.28-31,52,54 Although measures of 
contraceptive efficacy, such as the proportion of women using highly effective or prescription 
methods, remain predominant in family planning research and assessment of public health 
programs, calls are increasing to create more patient-centered measures of contraceptive access 
and use.21,26 Assessing agreement between currently used contraceptive methods and contraceptive 
preferences or a stated preferred method aligns with a rights-based framework prioritizing patient 
preferences, and is one potential avenue for measure development.21,22 
Emerging data suggest that sizable proportions of women experience discordance between 
the contraceptive methods they are currently using and the methods they would prefer to use or 
feel would be best for them.103-106 This work has highlighted system-level barriers such as method 
costs and health care access inequities as the primary correlates of preference-use 
discordance.103,104,106 However, provider biases in contraceptive counseling,41,43 differences in 
method features valued by patients and health care providers,107 the extent to which preferred 
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method features correspond with available methods,54 and other factors may also impact women’s 
ability to obtain and use methods that align with their goals and preferences. Improved 
understanding of reasons for preference-use discrepancies is needed to address potential disparities 
and better support women in achieving reproductive autonomy. 
Women Veterans enrolled in the Veterans Affairs (VA) healthcare system are required to 
have access to a primary care provider (PCP) proficient in contraceptive management, and have 
access to the full range of FDA-approved contraceptive methods at low or no cost through a 
centralized pharmacy and device formulary.86,87 While women Veterans engaged in VA care use 
highly effective contraceptive methods such as IUDs and contraceptive implants at higher rates 
than women in the general US population,93 the extent to which Veterans’ current contraceptive 
methods match their preferences for an “ideal” method remains unknown. We therefore sought to 
examine agreement between self-reported ideal and current contraceptive use in a population with 
access to an integrated healthcare system. Using mixed methods, we aimed to evaluate agreement 
between ideal and currently used contraceptive methods among women Veterans, to identify 
characteristics associated with ideal-current method match, and to describe women’s reasons for 
non-use of their stated ideal method. 
2.2 Methods 
2.2.1  Study design and population 
Data are from the Examining Contraceptive Use and Unmet Need among Women Veterans 
(ECUUN) study.93 ECUUN recruited a nationally representative sample of 2,302 women Veterans, 
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ages 18-45, who had at least one primary care visit in the VA healthcare system within 12 months 
prior to study enrollment. Participants completed a cross-sectional, computer-assisted telephone 
survey regarding contraceptive use, reproductive histories, and contraceptive care received in VA. 
Surveys were administered by trained interviewers between April 2014 and January 2016. The 
survey completion rate was 83% among enrolled participants, and study participants were similar 
to non-participants from the sampling frame in terms of age, race/ethnicity, marital status, income, 
geographic region and presence of medical and mental illness. The institutional review boards of 
VA Pittsburgh healthcare system and the University of Pittsburgh approved this study. Full 
methodology has been previously reported.93 
This analysis includes women identified as at risk for unintended pregnancy (n=992), 
defined as sexually active with a man within one month prior to the study interview; not pregnant, 
trying to conceive, or up to 6 weeks postpartum; and with no history of infertility or hysterectomy. 
We additionally excluded 13 women who did not report an ideal method (n=2), reported “other” 
ideal methods not consistent with contraception options offered on the survey (n=7), or had 
missing data on current method type (n=4), for a study sample of 979 women. 
2.2.2  Measures 
Per standard definitions, current contraceptive use was defined as use of a method within 
one month prior to the study interview.11 Participants were asked whether they had used each of 
17 contraceptive methods in the past month, including no method or “other” (non-listed) methods; 
women could report use of multiple methods. Following assessment of current contraceptive 
methods, participants were asked, “If you could choose any method of contraception or birth 
control to prevent pregnancy, what would be your ideal choice?” Participants were read a list of 
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the same 17 method options, and asked to select a single response. If participants responded prior 
to hearing the entire list of methods, the interviewer confirmed that the participant considered that 
method to be ideal among all available methods, and offered to read the entire list again to be sure. 
Participants who did not report current use of their stated ideal method were additionally asked, 
“why aren’t you currently using this method of contraception?” Interviewers recorded open-ended 
responses verbatim.  
We assessed patient-, provider- and system-level characteristics as potential covariates 
based on theoretical or empirical associations with contraceptive preferences or use. Patient-level 
variables included age, race/ethnicity, marital status, education, annual household income, parity, 
body mass index (BMI), self-reported history of at least one medical condition (hypertension, 
coronary artery disease, thromboembolic disease, breast cancer, stroke, liver disease, HIV/AIDS, 
diabetes, migraines, lupus, or seizure disorder) or mental health disorder (depression, anxiety, post-
traumatic stress disorder, bipolar disorder or schizophrenia), history of military sexual trauma 
(MST), deployment history, and whether participants had additional, non-VA insurance. 
Race/ethnicity was dichotomized as non-Hispanic white vs. non-white due to small sample sizes 
for non-white subgroups. Provider-level variables were VA PCP gender and whether the 
participant sees their VA PCP for almost all medical care and/or for gynecologic care. System-
level factors included presence of and receipt of primary care in a VA women’s health clinic, 
presence of an on-site gynecologist, and census region of the primary care site. All variables were 
assessed using survey data except for census region, which was determined using administrative 
data. 
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2.2.3  Data analysis 
Frequencies and percentages were generated to describe overall sample characteristics and 
the distribution of reported ideal methods. Ideal method type was described by sample 
characteristics, and differences in proportions tested using chi-square tests, or Fisher exact tests if 
expected counts were less than n=5. Our primary outcome was agreement between ideal and 
currently used methods. Any use of the stated ideal method in the past month was considered a 
match, regardless of additional methods used. The number and percentage of women with ideal-
current method match was calculated for the total sample and by stated ideal method. We used 
unadjusted logistic regression to test bivariate associations between patient-, provider- and system-
level characteristics and method match. Adjusted logistic regression was used to identify factors 
associated with match while adjusting for other pertinent predictors; variables associated with 
match at the p<0.2 level in bivariate analyses were included in the adjusted model. Stata 14.2 
(StataCorp, College Station, TX) was used for all quantitative analyses. 
Among the subset of women with ideal-current method mismatch, we analyzed open-ended 
reasons for non-use of the ideal method. We used an inductive approach, in which codes were 
created as they arose from the data, rather than based on preconceived notions of what themes 
might be present. Colleen Judge-Golden read all responses, created a codebook of 19 unique codes 
with definitions and representative quotes, and coded all responses using the final codebook. A 
second coder (Tierney Wolgemuth, B.S.) independently coded all responses using the final 
codebook. Codes were not mutually exclusive, i.e. more than one code could be applied to each 
response as necessary. Cohen’s kappa was calculated using the full dataset as a measure of inter-
coder reliability. The average overall kappa was 0.88, with individual codes ranging from 0.74 to 
1. Following kappa calculation, the coders discussed discrepancies and coded all responses to 
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consensus for analysis. A total of 48 responses (14%) required a consensus discussion regarding 
the presence or absence of one or more codes. Content associated with each code was summarized, 
and related codes grouped into larger themes for interpretation and reporting. Microsoft Excel 
(Microsoft Corporation, Redmond, WA) was used for qualitative data management and coding. 
2.3 Results 
2.3.1  Sample characteristics 
Table 2 displays sample demographic and healthcare utilization characteristics. Among 
979 women Veterans at risk of unintended pregnancy, the median age was 34 (range 21-45), and 
55% were non-Hispanic white. The majority had a bachelor’s degree or higher (52%), were 
married or cohabitating (63%), were parous (71%), and reported at least one medical (54%) or 
mental (65%) illness. Over half reported a history of military sexual trauma (53%). 
2.3.2  “Ideal” contraceptive methods and match with current methods 
Participants reported a range of contraceptive methods that they considered “ideal” to 
prevent pregnancy (Table 3). IUDs were the most frequently cited ideal method by 215 women 
(22%), followed by partner vasectomy (19%), birth control pills (15%), and tubal ligation (14%). 
As shown in Appendix A, differences in ideal method type were observed according to numerous 
patient-level demographic characteristics, but not by provider or system-level factors. 
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Table 2 Sample characteristics of women Veterans at risk of unintended pregnancy 
Characteristic n (%) a 
Patient-level  
Age  
   20-29 222 (23) 
   30-34 320 (33) 
   35-39 251 (26) 
   40-45 186 (19) 
Race  
   Non-Hispanic white 538 (55) 
   Non-white 441 (45) 
Marital Status b  
   Single, never married 142 (15) 
   Married or Cohabitating 621 (63) 
   Formerly Married 215 (22) 
Education   
   Bachelor's degree or higher 507 (52) 
Annual household income b  
   < $20,000 174 (18) 
   $20,000-$59,999 506 (52) 
   >= $60,000 289 (30) 
Parous (≥1 live birth) b 698 (71) 
Body Mass Index b  
  Underweight/Normal (<25) 328 (34) 
  Overweight (25 to <30) 324 (33) 
  Obese (≥ 30) 324 (33) 
Medical Illness 530 (54) 
Mental Illness 640 (65) 
History of Military Sexual Trauma 514 (53) 
Ever Deployed b 537 (55) 
Has additional (non-VA) insurance b 520 (53) 
Provider-level  
VA PCP is female b 760 (79) 
Sees VA PCP for almost all care b 772 (80) 
Sees VA PCP for gynecologic care b 558 (58) 
System-level  
Primary Care in VA WHC  
   No WHC at site, or don’t know 312 (32) 
   WHC at site, not seen there 215 (22) 
   WHC at site and seen there 452 (46) 
On-site gynecologist 601 (61) 
Census Region  
   Northeast 82 (8) 
   Midwest 188 (19) 
   South 503 (51) 
   West 206 (21) 
 
Abbreviations: VA, Veterans Affairs; PCP, primary care provider; WHC, women’s health clinic. 
a N=979. Percentages may not add to 100% due to rounding. 
b Missing data: marital status (n=1), annual household income (n=10), parity (n=2), BMI (n=3), deployment (n=1), 
additional insurance (n=1), VA PCP gender (n=12), sees VA PCP for all care (n=10) and gynecologic care (n=17). 
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Table 3 Women Veterans’ ideal contraceptive methods and match with current method(s) 
 Identified as “ideal” method 
Percent currently 
using their stated 
ideal method 
Method n (column %) n (row %) 
Intrauterine device (IUD) 215 (22) 156 (73) 
Partner's vasectomy 189 (19) 69 (37) 
Birth control pills 142 (15) 95 (67) 
Tubal ligation 133 (14) 94 (71) 
Male condoms 83 (8) 45 (54) 
Depo-Provera injections 55 (6) 27 (49) 
Contraceptive implant 44 (4) 25 (57) 
Vaginal ring 43 (4) 30 (70) 
Natural family planning 41 (4) 15 (37) 
Withdrawal 14 (1) 9 (64) 
Patch 8 (1) 2 (25) 
No method 7 (1) 2 (29) 
Female condom 2 (0) 0 (0) 
Spermicides 1 (0) 1 (100) 
Sponge/Diaphragm/Cap 1 (0) 0 (0) 
Emergency contraception 1 (0) 0 (0) 
Total 979 (100) 570 (58) 
 
 
Overall, 570 women (58%) reported current use of their stated ideal method. A single 
participant reported spermicide as both her ideal and current method, resulting in 100% match for 
this method. Otherwise, match was greatest among women who selected an IUD as their ideal 
method (73% currently using), followed by tubal ligation (71% currently using).  
2.3.3  Factors associated with ideal-current method match 
In bivariate analyses, non-white women were less likely to report ideal-current method 
match compared to non-Hispanic white women (54% match vs. 62%, respectively; p=0.02), as 
were women with a history of at least one mental health disorder compared to women with no 
history of mental illness (55% match vs. 64%, respectively; p=0.01) (Table 4). Presence of a 
gynecologist at the VA primary care site was associated with increased ideal-current match (61% 
match vs. 54% with no on-site gynecologist, p=0.045). 
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Table 4 Associations of sample characteristics with ideal-current method match 
   Match of Ideal & Current Method; n= 570 (58.2%) 
Characteristic % Match 
Unadjusted OR a 
(95% CI) 
p-
value 
Adjusted OR b 
(95% CI) 
p-
value 
Patient-level      
Age   0.60  - 
   20-29 58 Ref.  -  
   30-34 60 1.09 (0.77, 1.54)  -  
   35-39 55 0.90 (0.62, 1.29)  -  
   40-45 61 1.14 (0.76, 1.69)  -  
Race   0.02  0.004 
   Non-Hispanic white 62 Ref.  Ref.  
   Non-white 54 0.74 (0.57, 0.96)  0.68 (0.52, 0.89)  
Marital Status   0.66  - 
   Single, never married 55 Ref.  -  
   Married or Cohabitating 59 1.16 (0.81, 1.68)  -  
   Formerly Married 60 1.21 (0.79, 1.85)  -  
Education    0.59  - 
   Less than college degree 59 Ref.  -  
   Bachelor's degree or higher 57 0.93 (0.72, 1.20)  -  
Income   0.70  - 
   < $20,000 58 Ref.  -  
   $20,000-$59,999 59 1.06 (0.75, 1.51)  -  
   >= $60,000 56 0.94 (0.64, 1.37)  -  
Parity   0.37  - 
   Nulliparous  61 Ref.  -  
   Parous (≥1 live birth) 57 0.88 (0.66, 1.17)  -  
Body Mass Index   0.62  - 
   Underweight/Normal (<25) 60 Ref.  -  
   Overweight (25 to <30) 56 0.86 (0.63, 1.18)  -  
   Obese (≥ 30) 59 0.97 (0.71, 1.32)  -  
Medical Illness   0.17  0.45 
   Yes 56 0.84 (0.65, 1.08)  0.90 (0.69, 1.17)  
   No   61 Ref.  Ref.  
Mental Illness   0.01  0.01 
   Yes 55 0.70 (0.54, 0.92)  0.69 (0.52, 0.92)  
   No 64 Ref.  Ref.  
History of Military Sexual Trauma   0.67  - 
   Yes 58 0.95 (0.73, 1.22)  -  
   No 59 Ref.  -  
Ever Deployed   0.64  - 
   Yes 59 1.06 (0.82, 1.37)  -  
   No 57 Ref.  -  
Additional (non-VA) insurance   0.48  - 
   No 57 Ref.  -  
   Yes 59 1.10 (0.85, 1.41)  -  
Provider-level      
VA PCP is female    0.96  - 
   Yes 58 1.01 (0.74, 1.37)  -  
   No 58 Ref.  -  
Sees VA PCP for almost all care   0.28  - 
   Yes 59 1.19 (0.87, 1.63)  -  
   No 55 Ref.  -  
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Table 4 (continued)      
   Match of Ideal & Current Method; n= 570 (58.2%) 
Characteristic n (%) Unadjusted OR
 a 
(95% CI) 
p-
value 
Adjusted OR b 
(95% CI) 
p-
value 
Sees VA PCP for gynecologic care   0.25 - - 
   Yes 60 1.17 (0.90, 1.51)  -  
   No 56 Ref.  -  
System-level      
Primary Care in VA WHC   0.28  - 
   No WHC or don’t know 57 Ref.  -  
   Yes WHC, not seen there 55 0.93 (0.65, 1.32)  -  
   Yes WHC and seen there 61 1.19 (0.88, 1.59)  -  
On-site gynecologist   0.045  0.03 
   Yes 61 1.31 (1.006, 1.69)  1.35 (1.03, 1.75)  
   No/Don’t know 54 Ref.  Ref.  
Census Region   0.51  - 
   Northeast 66 Ref.  -  
   Midwest 57 0.68 (0.40, 1.18)  -  
   South 57 0.69 (0.43, 1.13)  -  
   West 59 0.74 (0.43, 1.26)  -  
 
Abbreviations: VA, Veterans Affairs; PCP, primary care provider; WHC, women’s health clinic.  
Percentages may not add to 100% due to rounding. Bolded cells indicate statistically significant results. 
a Unadjusted logistic regression models with outcome of match vs. no match by sample characteristics. n=979 except 
for variables with missing data, as noted in Table 2. 
b Adjusted logistic regression model with outcome of match vs. no match; variables associated with match in bivariate 
analyses at the p<0.2 level were included in the adjusted model. n=979 (no missing data for included variables). 
 
 
 
In a model adjusting for race/ethnicity, mental illness, medical illness, and on-site 
gynecology (Table 4), ideal-current match remained significantly negatively associated with both 
non-white race (aOR 0.68; 95% CI: 0.52, 0.89) and mental illness (aOR 0.69; 95% CI: 0.52, 0.92). 
Presence of an on-site gynecologist remained positively associated with match (aOR 1.35; 95% 
CI:1.03, 1.75). Medical illness was not associated with match in the adjusted model. 
2.3.4  Reasons for ideal-current method mismatch 
Among 409 women with ideal-current method mismatch, 340 (83%) provided open-ended 
reasons for current non-use of their stated ideal method. Due to survey skip patterns, 68 women 
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with ideal-current mismatch were not asked this open-ended question – 63 were women who 
reported no contraceptive use in the past month, and 5 were women who reported “no method” as 
ideal. One woman was asked the open-ended question but did not provide a response. Qualitative 
analysis of open-ended responses revealed varied reasons for mismatch, which were classified into 
“modifiable barriers” to ideal method use, and “non-modifiable or personal factors” related to ideal 
method non-use (Table 5). 
 
 
Table 5 Women Veterans’ reasons for non-use of a stated ideal method  
Reason for non-use of ideal method Frequency (%) a 
Modifiable barriers 78 (23) 
     Access issues 38 (11) 
     Cost 19 (6) 
     Provider barrier 14 (4) 
     Need (more) information 20 (6) 
Non-modifiable/personal reasons 267 (79) 
     Using another method 95 (28) 
     Pregnancy plans/goals 62 (18) 
     Partner influence  55 (16) 
     Concern for side effects 23 (7) 
     Contraindication to ideal method 14 (4) 
     Ideal method inconvenient 11 (3) 
     Ideal method not necessary in  
           relationship context 11 (3) 
     Lack of permanent sexual partner  7 (2) 
     Not sexually active (enough) 7 (2) 
     General fear re: ideal method 5 (2) 
     Perceived subfertility 1 (0.3) 
     Non-specific reason 14 (4) 
In process of obtaining ideal  11 (3) 
 
a n=340 women with ideal-current mismatch who provided an open-ended reason for current non-use of their stated 
ideal contraceptive method (83% of n=409 women with mismatch). Percentages do not add to 100% because codes 
were not mutually exclusive; 278 responses were assigned a single code (82%), 57 responses were double-coded 
(17%), and 5 responses had three codes (2%). 
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2.3.4.1 Modifiable barriers to ideal method use 
Overall, 78 women (23%) reported a potentially modifiable barrier to current use of their 
ideal method, including barriers to accessing health care or specific methods; concerns about cost; 
and provider-level barriers. Access issues were described by 38 women (11%), with 23 mentioning 
barriers specific to VA. Several cited scheduling difficulties or unavailability of VA providers as 
reasons for ideal method non-use, explaining, “the VA usually has a month wait to get my birth 
control pills,” or “it takes a while to get in to a VA OBGYN.” Eleven women stated that their ideal 
method is not offered by VA, with most describing misconceptions based on rumor or hearsay. 
One woman explained, regarding an IUD, “I don't know if it was available, I heard rules that you 
had to be married in order to get it from the VA.” However, a few women described having directly 
experienced unavailability of a desired method, such as one was not using her ideal method of an 
IUD, “because I went to the VA and they told me that they only give you pills.” Another woman 
whose ideal method was Depo-Provera explained, “it wasn't offered when I got on birth control. 
Or they didn't have it at the VA, or something like that.” 
Concerns about costs were cited by 19 women (6%) as a reason for non-use of ideal 
methods ranging from hormonal methods to sterilization procedures. While such concerns were 
often not well-explained (“It's expensive;” “It cost too much”), numerous stemmed from perceived 
lack of insurance coverage for ideal methods, for example, “my insurance won't cover it and it's 
really expensive,” regarding an IUD. Although cost concerns generally reflected misconceptions 
about VA contraceptive coverage, 5 women identified lack of coverage for a partner’s vasectomy 
as a gap in their VA benefits. One explained, “we don't have the money for me to talk him into 
doing that, and that's not covered by the VA, because he's not the Veteran.” 
Provider-level barriers to use of an ideal method were described as a reason for mismatch 
by 14 women (4%). Several women described receiving misinformation about their ideal method 
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from a provider, such as one who explained, “I was told I had to have a baby first, or its easier to 
get implemented after a birth,” regarding an IUD. Others perceived provider biases against 
particular methods, such as a woman whose ideal method was Depo Provera, who said, “I actually 
asked for it from my doctor, and he gave me a list of side effects. He recommended that I stick 
with the pill.” Another woman described the impact of conscientious objection from a VA 
provider, explaining, “The VA doctor said it was against his religion and wouldn’t give [the pill] 
to me. So they've put me on a list for another doctor.” Half of the women who reported provider 
barriers cited tubal ligation as their ideal method (n=7/14). One explained, “I just turned 25 and 
my doctor didn't want to do it when I was young.” Others described refusal from providers to even 
discuss sterilization as an option, such as one woman who explained, “Usually my doctor says that 
it is too extreme of a choice.” 
Finally, twenty women cited a need for additional information about their stated ideal 
method as a potentially modifiable barrier to use. Most of these women expressed a need to discuss 
features or side effects of a prescription or procedural method with their doctor prior to initiation, 
or to get information regarding VA’s provision or coverage of the method. However, several 
women described needing more information about non-prescription methods such as female 
condoms (“I wasn't very aware that there were any”) or natural family planning (“I just don't know 
enough about it. There's a lot of learning that goes into it”). 
2.3.4.2 Non-modifiable/personal factors related to ideal method non-use 
A total of 267 women (79%) reported non-modifiable or personal reasons for ideal-current 
method mismatch, including partner influences and relationship contexts; pregnancy plans 
incongruent with ideal method use; perceived medical contraindications and side effects; and 
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current use of another method. While some non-modifiable reasons reflect circumstantial barriers 
to ideal method use, others suggest limitations of our measure of “ideal” contraceptive methods. 
The direct influence of a romantic or sexual partner was cited as a reason for non-use of an 
ideal method by 55 women (16%), with partner vasectomy being the selected ideal method in 
nearly all of these instances (n=52). Women explained non-use of vasectomy in terms of their 
partners’ decisions, for example, “Because it's not my choice. It's my partner's choice.” Numerous 
women described a partner’s fears about the procedure, such as, “he's scared and won't get it done,” 
while several described partners’ concerns about diminished masculinity with vasectomy saying, 
for example, “my husband said he'd feel like less of a man.” For others, absence of a permanent 
partner precluded use of vasectomy as an ideal method. One woman explained, “I'm not in a 
serious long-term relationship, so I feel like I don't have the right to ask that of someone.” Aside 
from vasectomy, a few women described their partner as the primary reason for non-use of another 
method, such as one woman who reported, “my husband doesn’t like [condoms].” Distinct from 
direct partner influences, multiple women mentioned that non-use of an ideal method of condoms 
occurred in the context of trusting relationships, either by describing the social context of the 
relationship (e.g. “I’m married”), or implying low risk of STD transmission (“We have been 
together for two years, and I don't know, I trust him that he isn't going to sleep around”). 
Sixty-two women (18%) described incompatibility of their stated ideal method with current 
or future childbearing plans as a reason for current non-use of the ideal method, suggesting that 
many women may have interpreted the word “ideal” in the abstract, rather than within their current 
life contexts. Having reported an IUD as ideal, one woman explained, “We're going to start trying 
again in April. We would not be heartbroken if we ended up pregnant before April. We're fine with 
using condoms until April. After the next baby we'll pick the IUD again.” Multiple women who 
selected tubal ligation or vasectomy as their ideal method similarly indicated that this method was 
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not currently appropriate due to future childbearing goals. With regards to partner vasectomy, one 
woman explained, “We're just waiting a few more years just to be sure we don’t want more kids.” 
Conversely, numerous women cited completion of childbearing as a reason for non-use of 
reversible ideal methods, such as one who explained relying on her tubal ligation rather than her 
stated ideal method of Depo-Provera, saying, “I decided I never want to have any more kids, and 
I made a permanent choice instead of a temporary choice.” Another who cited the implant as ideal 
explained, “my husband's had a vasectomy. Our family-- we're done with our kids. Our kids are 
growing up.” Such responses nearly always suggested that the already obtained permanent method 
was actually superior to the stated ideal method given the respondent’s life context. 
Other reasons for ideal-current mismatch that suggest differential interpretation of the word 
“ideal” include contraindications and side effects, inconvenience of the ideal method, and current 
use of a different method. Fourteen women (4%) indicated that their stated ideal method was not 
available to them due to potential contraindications. One woman explained that she cannot use the 
pill, “because I smoke, and I’m over 35,” while another described a contraindication to male 
condoms, stating, “I have an allergy to latex and to spermicide.” Similarly, 23 women (7%) 
described potential or experienced side effects as reasons for non-use, such as one who said, “I 
had a lot of bad side effects from hormones before” to explain her non-use of the ring. Others 
explained that their stated ideal method was actually too inconvenient within their life contexts. 
Regarding non-use of the pill, one woman explained, “my life is too busy, I forget to take them,” 
while another reported she could not practically use her ideal method of natural family planning, 
“because it's not a perfect world, and I don't have the ability to think about that at the time.” Finally, 
95 women (28%) described current use of a different contraceptive method as a reason for non-
use of their stated ideal method (e.g. “I have my tubes tied,” “I chose the IUD”), with 69 citing 
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this as the sole reason for mismatch. These responses often implied that the currently used method 
was working for them at this time, or was in fact superior to the stated ideal method. 
2.4 Discussion 
Despite engagement in an integrated healthcare system offering low or no cost access to 
the full range of contraceptive methods, current use of a stated “ideal” contraceptive method was 
reported by only 58% of female VA enrollees at risk of unintended pregnancy, with non-white 
women and women with mental illness having reduced odds of ideal-current method match and 
women with a gynecologist at their VA care site having increased odds of match. Nearly one 
quarter of women reported a potentially modifiable barrier to current use of their ideal method, 
such as access issues, cost concerns or provider barriers; however, 79% of responses included non-
modifiable or personal factors, many of which suggest that women may have interpreted the word 
“ideal” in the abstract, rather than within their current life contexts. 
Our finding of substantial levels of mismatch between stated ideal and currently used 
methods aligns with emerging work examining contraceptive preference matching in other 
settings. Among a recent national sample of US women, 36% were not “currently using the type 
of birth control that [they] would most like to use.”103 Similarly, stated preferences for certain 
methods were found to greatly exceed actual use among samples of college and postpartum women 
in Texas, particularly for long-acting reversible methods and sterilization.104,106 In these studies, 
method costs and inadequate health care access are highlighted as the primary reasons for 
preference-use discordance.103,104,106 In contrast, system-level barriers were far less common 
reasons for ideal method non-use among our sample of women Veterans. This is not surprising 
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given our study population’s uniform access to an integrated healthcare system through VA 
enrollment, as compared to more heterogeneous access to health care among US women. 
Nevertheless, women in our study identified barriers to VA health care that may have contributed 
to non-use of an ideal method, such as long wait times and provider unavailability. Our finding 
that an on-site gynecologist at the VA primary care location was independently associated with 
increased ideal-current method match suggests that proximity to specialized gynecologic care may 
contribute to preference matching or the overall convenience of contraceptive method acquisition. 
This result is consistent with prior work noting associations of on-site gynecology with access to 
reproductive health services, particularly provision of procedural contraceptive methods such as 
IUDs and implants.92,108  
Misconceptions about VA contraceptive benefits was another prominent barrier to ideal 
method use identified in our study, with a number of women reporting erroneous beliefs that VA 
does not offer or cover particular methods. This result highlights a need to improve patient 
awareness of VA contraceptive services. However, women Veterans may indeed experience 
financial barriers to contraceptive use despite their access to VA health care. First, in contrast to 
most insured US women who have zero cost-sharing for contraception under the Affordable Care 
Act,71 a significant subset of VA enrollees incur copayments for contraceptive medications.86 
Copayments have been associated with reduced adherence to hormonal contraception in VA 
populations,109 and may serve as a barrier to contraceptive use. Furthermore, as multiple women 
pointed out, VA does not cover vasectomy for Veterans’ male partners, precluding access to this 
method for some based on financial means.  
Women in our study also reported provider-level barriers to use of ideal contraceptive 
methods. Several responses suggested gaps in provider knowledge or expertise despite VA’s 
policy of requiring access to a PCP proficient in contraceptive management.87 Other provider-level 
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obstacles to ideal contraceptive use are similar to those identified in the general population, such 
as pressure to use specific methods endorsed by a provider,42,43 discouragement from using a 
method of choice, particularly in the case of female sterilization,110,111 and conscientious refusal, 
which can produce substantial access barriers in reproductive health care.112 Our findings highlight 
the ongoing need across healthcare settings to promote evidence-based, patient-centered and non-
biased counseling strategies which elicit and respect the primacy of patient preferences in 
contraceptive method selection.21,63 
Reduced ideal-current match among non-white women and women with mental illness 
observed in this study is concerning, and is likely reflective of broader health care disparities. 
Differences in contraceptive use by race/ethnicity are well established, with non-white women 
being less likely to use any contraception and prescription methods in both the general US 
population49 and among our sample of women Veterans.95 Reasons for such discrepancies are 
complex and multifactorial, including structural inequalities such as health care access 
disparities,50 disparities in contraceptive knowledge,96 and differential preferences for certain 
method features.30,54 Consistent with prior research on contraceptive preferences, greater 
proportions of non-white women in our study cited non-prescription and barrier methods as ideal 
as compared to non-Hispanic white women.54 Women of minority race/ethnicity and other socially 
marginalized identities are also particularly vulnerable to biased or coercive contraceptive 
counseling,41,43,67 which could impede their ability to use prescription methods aligned with their 
preferences. Prior analyses from the ECUUN study have found that perceived race-based 
discrimination while seeking VA health care is associated with reduced odds of using prescription 
contraceptive methods independent of race/ethnicity, suggesting that negative interactions with 
providers or the healthcare system at large may directly impact contraceptive use.95 
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Prior analyses from the ECUUN study revealed no significant differences in overall 
contraceptive use or method effectiveness according to mental health status, which was interpreted 
as evidence of equitable service delivery to women with and without mental health disorders.98 
Our novel finding of reduced ideal-current method match among this same population of women 
Veterans with mental illness underscores the inability of efficacy-based metrics to account for 
method preferences or satisfaction, and the potential promise of measures based on preference 
matching to better assess contraceptive access and equity. Further research is needed to better 
understand reasons for preference-use mismatch in this vulnerable population. 
Despite the potential advantages of measuring contraceptive preferences, methodological 
challenges remain. Prior work has found that preferences for specific method features do not 
necessarily align with or predict chosen contraceptive methods,29,113 suggesting that a single 
method meeting all desired criteria may not exist for many women. Similarly, the high prevalence 
of contextual reasons for ideal-current method mismatch in our study draws attention to the 
complexity of contraceptive decision-making, and to potential limitations of our outcome measure. 
By asking women to select a single “ideal” method rather than asking about specific method 
features, our measure left room for the chosen method to have both pros and cons. However, the 
complexity of our qualitative results suggest that many women interpreted the word “ideal” in an 
abstract sense rather than within their current life circumstances. As such, caution should be used 
in interpreting our quantitative measure of ideal-current match as an indicator of disparity.  
Other studies examining preference-use discordance have asked women to identify the 
method they would “most like to use … regardless of cost of other difficulties,”103 or “if you could 
use any birth control method you wanted.”104 However, this type of language may also be subject 
to variable interpretation. For instance, in He et al.’s study of US women at risk of unintended 
pregnancy,103 “lack of perceived/actual need” for the preferred method was the second most 
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commonly cited reason for preference-use mismatch, after cost and insurance concerns. Other 
reasons for non-use of the preferred method included “pregnancy ambivalence” and “fear of side 
effects and health concerns.”103 These reasons are similar to the non-modifiable reasons for ideal 
method non-use identified in our study, and suggest that mismatch is not necessarily suboptimal 
in the context of respondents’ life contexts. Clearly, optimization of preference-based measures 
remains incomplete.  
Strengths of this study include a large sample size relative to prior work and our ability to 
examine preference-use matching in a population with relatively homogeneous access to health 
care. There are also several limitations. First, small sample sizes for qualitative reasons for ideal-
current mismatch leave us unable to examine statistical differences in reasons for mismatch across 
patient characteristics. Next, due to survey skip patterns, we are missing qualitative data for women 
not using contraception (n=63) or who stated that their ideal method was no method (n=5). These 
women may have had unique reasons for ideal method non-use, which we are unable to explore. 
Finally, our qualitative results suggest that asking about an “ideal” method may have encouraged 
women to consider contraceptive preferences outside of their current life contexts. The evident 
variability in participants’ interpretation of the word “ideal” is a significant limitation of our work, 
and suggests that this measure may not be a valid marker of access or disparity. 
In conclusion, healthcare-related barriers to use of preferred contraceptive methods persist 
even among women Veterans with access to the full range of contraceptive methods through an 
integrated healthcare system. Continued efforts are needed to ensure that Veterans are informed of 
their insurance benefits and available contraceptive options, and that providers deliver accurate 
and person-centered counseling. However, the factors that influence women Veterans’ perceived 
ideal contraceptive methods and drive their ability to use those methods at a given time are 
complex, and include both modifiable and contextual elements. While our qualitative findings 
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suggest limitations to asking about an “ideal” contraceptive method, this work contributes to a 
growing evidence base demonstrating that measures of contraceptive use and method efficacy are 
insufficient as markers of contraceptive access or reproductive autonomy. Our results underscore 
the ongoing need for new measures that can more fully assess women’s abilities to select, access 
and use contraception in accordance with their goals and preferences. 
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3.0 Financial Implications of 12-month Dispensing of Oral Contraceptive Pills in the 
Veterans Affairs Health Care System 
This manuscript is reproduced with permission from JAMA Internal Medicine. 2019. 
Published online July 08, 2019. doi:10.1001/jamainternmed.2019.1678. Copyright©2019 
American Medical Association. All rights reserved.114 
3.1 Introduction 
The Veterans Affairs (VA) healthcare system is the largest integrated healthcare system in 
the United States115 and provides care to a growing population of reproductive-aged women 
Veterans, including provision of all contraceptive methods approved by the US Food and Drug 
Administration.77,87 Similar to within the general US population, oral contraceptive pills (OCPs) 
are among the most commonly used methods of contraception among women Veterans.93 To be 
most effective at preventing pregnancy, OCPs require adherence to daily use, timely medication 
refills, and prescription renewals. Missing more than 2 consecutive pills can increase a woman’s 
chance of contraceptive failure and thus the potential for unintended pregnancy.116 The effects of 
this user dependence are evidenced by dramatic differences between perfect and typical use failure 
rates for OCPs (0.3% and 9.0% in the first year of use, respectively).117 
Although OCP prescriptions can be written for a full year, pill pack quantity per fill is 
primarily determined by the patient’s insurance. In the US, medication dispensing is typically 
limited to 30-, 60-, or 90-day supplies, as a mechanism designed to control costs.74,118 Three-month 
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supplies are increasingly common among commercial and public insurers owing to associations 
with improved adherence and cost savings for patients and payers.119-122 Nevertheless, 90-day 
limits still necessitate multiple refills annually. Gaps in OCP coverage due to prescription refill 
delays are an established barrier to perfect contraceptive use among US women.123,124  
Like most US health plans, VA stipulates a 3-month dispensing limit for all prescription 
medications, including OCPs. However, VA data indicate that 43% of women dispensed 3-month 
contraceptive supplies experience at least 1 gap of at least 7 days between refills during the course 
of a year of use.125 Conversely, US women dispensed 12-month contraceptive supplies experience 
fewer gaps and improved method continuation compared to women receiving fewer pills 
upfront,75,126,127 which in turn leads to reductions in unintended pregnancy and abortion.76 Citing 
this research, international and US guidelines now recommend routine initial dispensing of up to 
1-year supplies of hormonal contraception.116,128 
Despite mounting evidence favoring 12-month dispensing strategies for improving 
contraceptive access and reproductive outcomes, the financial consequences for VA are unclear, 
and will likely shape policy decisions. We used decision modeling to estimate financial and 
reproductive health implications to VA of a revised policy allowing for 12-month dispensing of 
OCPs. Based on existing data, we hypothesized that 12-month dispensing would reduce VA costs 
while decreasing unintended pregnancies among women Veterans. 
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3.2 Methods 
3.2.1  Model design and cohort 
The institutional review board of VA Pittsburgh healthcare system determined this study’s 
use of retrospective administrative data to be exempt from human subjects review. Additional 
approval was obtained from the VA Pharmacy Benefits Management Service to utilize 
administrative data. This study followed the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) reporting guideline for economic evaluation. 
We developed a decision analysis model from the VA payer perspective to estimate 
incremental costs of a 12-month OCP supply option (twelve 28-day pill packs) compared with 
conventional 3-month dispensing (three 28-day packs dispensed 4 times). Figure 2 shows a 
simplified model schematic. The 12-month strategy is modeled as an option to account for personal 
preference (e.g. trialing a new pill type) and because some VA enrollees are subject to copayments 
for contraceptive medications,89 which may disincentivize some women from accepting a 12-
month supply. The model was run over a time horizon of twelve 28-day periods (approximately 
one year). 
Our model assumes a cohort of reproductive-aged, heterosexually active female VA 
enrollees who wish to avoid pregnancy for at least 1 year. Pregnancy outcomes include abortion, 
miscarriage (pregnancy loss before gestational age of 20 weeks) and live birth. Stillbirths (fetal 
death after gestational age of 20 weeks) and ectopic pregnancies were excluded for model 
parsimony because these outcomes represent less than 2% of pregnancies, and because pregnancy 
outcome probabilities are not expected to differ between strategies.129,130 Model outcomes were 
per-woman average costs for 3-month and 12-month dispensing, the incremental cost difference 
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between strategies, and total incremental annual cost difference among all women using OCPs. A 
cohort of 24,309 women was used to calculate total annual costs, based on the number of VA 
enrollees who filled an OCP prescription during fiscal year 2017 (FY2017). Model construction 
and analyses were performed using TreeAge Pro 2018 and 2019 software (TreeAge Software, 
Williamstown, MA). Independent coding of model components and review of model accuracy by 
Colleen Judge-Golden and Kenneth Smith, MD, MS, was used to reduce risk of model errors or 
programming bugs (internal validity).131 
 
 
 
 
Figure 2 Decision model schematic 
Decision analysis model of 3- vs. 12-month dispensing strategies for oral contraceptive pills (OCPs). Rx indicates 
prescription.  
Figure reproduced with permission from JAMA Internal Medicine. 2019. Published online July 08, 2019. 
doi:10.1001/jamainternmed.2019.1678. Copyright©2019 American Medical Association. All rights reserved. 
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3.2.2  Key assumptions 
Base case analyses assume that 50% of OCP users opt to receive a 12-month supply of 
OCPs, and this value was varied from 0% to 100% in sensitivity analyses; cohorts choosing 12- 
versus 3-month supplies are assumed to be identical in demographic factors and unintended 
pregnancy risk. Based on a cohort wishing to avoid pregnancy for at least 1 year, all pregnancies 
in the model are unintended (i.e. occurring sooner than desired or when no future pregnancies were 
desired, per standard definitions).11 This assumption informs the base case proportion of 
pregnancies that result in abortion (42%).13 Although empirical evidence indicates that 
continuation of OCP use is improved among women dispensed greater numbers of pills,125,126 
discontinuation rates are equivalent between the 3- and 12-month strategies, and treated as a single 
variable in the model, biasing against the 12-month strategy. The model assumes an equal 
probability of daily contraceptive adherence between 3- and 12-month cohorts (i.e. if women have 
no gaps in pill coverage, they are equally likely to take pills consistently). Typical use failure rates 
are used to account for imperfect daily adherence.117 Finally, pregnancy risk is assumed to be 
constant on average over time, allowing for pregnancy risk prorating based on time covered by 
OCPs. 
3.2.3  Model parameters 
Model parameters are listed in Table 6. Probabilities of contraceptive continuation, 
coverage gaps, pregnancy, and pregnancy outcomes were drawn from published 
literature.13,93,117,125,132,133 Our model does not allow for switching from OCPs to other prescription 
contraceptive methods over the 1-year time horizon. However, prior work indicates that 
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prescription contraceptive method switching is low among VA enrollees using hormonal 
contraception (4.8% switched to another short-acting method over 1 year)125 and among non-VA 
women using OCPs (average of 0.11 OCP cycles wasted annually owing to method switching).76 
Women discontinuing use of OCPs are assumed to use nonprescription methods or no method for 
the remainder of the time horizon. The base case pregnancy risk among those who discontinue 
OCP use is a weighted average of annual typical use failure rates for condoms, withdrawal, fertility 
awareness methods, spermicides and no contraceptive use, based on the distribution of use of these 
methods among a nationally representative sample of women Veterans who use VA for primary 
care.93,117 Women with gaps between OCP refills are assumed to use no contraception during gaps, 
with an 85% annual pregnancy risk.117 Pregnancy probabilities are prorated based on OCP 
coverage time versus gap or discontinuation. All annual pregnancy probabilities were additionally 
prorated to account for a model time horizon of twelve 28-day cycles (336 days) rather than 365 
days. 
Costs were drawn from VA administrative data. Intermediate costs include the average cost 
of pills (including fixed and variable supply costs and overhead) and average dispensing costs 
(including labor and, for mail-order prescriptions, supplies and overhead) for each 3-month OCP 
supply; average costs include prescriptions filled at pharmacy windows and via VA’s mail-order 
pharmacy in FY2017. Intermediate costs were multiplied by 4 in 12-month dispensing arms, and 
scaled in 3-month dispensing arms based on the minimum number of 3-month supplies required 
to account for average OCP coverage time in that arm (e.g. multiplied by 3 for discontinuers in the 
base case to account for an average of 8 months OCP coverage). Our assumption of direct 
scalability for pill and dispensing costs from 3- to 12-month supplies biases against the 12-month 
option, as dispensing of larger quantities may be associated with reduced per-unit costs and thus 
lower relative intermediate costs.  
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Table 6 Parameters for base case and sensitivity analyses 
  
Base 
Case 
One-way Sensitivity 
Analysis a 
Probabilistic 
Sensitivity Analysis b 
 
Parameter Low Value High Value SD Dist Reference 
 COSTS (2017 US $)       
   Intermediate Costs c       
      3-month OCP supply  $38.48 $0.01 $5,000.00 $100.68 gamma VA data 
      Dispensing for 3-month OCP supply  $8.58 $0.01 $110.00 $6.70 gamma VA data 
      Copayment for 3-month OCP supply -$24.00 - - - - 134 
   Outcome Costs       
      Live Birth       
         Prenatal care d $2968.79 $100.00 $15,000.00 $3789.39 gamma 132 
         Intrapartum/delivery care $7933.67 $1,000.00 $100,000.00 $6827.42 gamma VA data 
         Newborn care (7 days) $6480.85 $300.00 $100,000.00 $6000.00 gamma VA data 
      Miscarriage $1186.41 $100.00 $5,000.00 $1452.71 gamma VA data 
      Abortion $0 - - - - 135 
 PROBABILITIES       
   Choose 12-month supply 0.50 0 1.00 0.20 beta Assumption 
   Have copayments for OCPs 0.35 0 1.00 0.10 beta VA data 
   OCP use probabilities        
      Discontinue OCPs given 3 or 12 months  0.35 0 0.70 0.10 beta 125; assumption 
      ≥ 1 gap in coverage given 3 months 0.43 0 0.70 0.15 beta 125 
   Annual pregnancy probabilities e       
      Pregnancy given continuous OCP use 0.09 0 0.20 0.05 beta 117 
      Pregnancy given discontinued OCPs f 0.47 0 1.00 0.15 beta 93,117 
      Pregnancy during OCP coverage gap(s) 0.85 0 1.00 0.08 beta 117; assumption 
   Pregnancy outcome probabilities       
      Miscarriage 0.10 0 0.40 0.07 beta 133 
      Abortion 0.42 0 0.70 0.05 beta 13 
      Live birth 0.48 - - - - - 
      Pregnancy paid for by VA 0.52 0 1.00 0.20 beta 93; assumption 
      Newborn care paid for by VA g 0.58 0 1.00 0.20 beta VA data 
 DURATIONS (months) 
      
   OCP use given ≥ 1 coverage gap 10 3 11.75 h 1 beta 125 
   OCP use given discontinuation of OCPs 8 0 12 1.5 beta 125 
 
Abbreviations: SD, standard deviation; Dist, distribution; OCP, oral contraceptive pill; VA, Veterans Affairs 
a Cost ranges for one-way sensitivity analysis are based on extremes of empirical VA data. All other ranges are based 
on published literature and are intentionally broad to reflect parameter uncertainty and allow for extreme value 
analysis.136 
b Distributions means are equal to the base case. Distributions were chosen based on established best practices.136 
c Intermediate costs are scaled directly based on the minimum number of 3-month supplies necessary to account for 
time covered by OCPs, or multiplied by 4 for 12-month supplies. 
d Prenatal care costs are based on average costs paid by commercial insurers for prenatal care in 2010 ($2641), adjusted 
to 2017 US dollars. 
e Based on 1 full year of use and prorated in the model to account for the proportion of time in a given state (covered 
by OCPs, OCP use gap, or discontinuation of OCP use), and for a time horizon of twelve 28-day periods (336 days) 
instead of a full calendar year. 
f The base case probability is a weighted average of annual typical use failure rates for nonprescription contraceptive 
methods (male condoms, withdrawal, fertility awareness-based methods and spermicides) and no method use, based 
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on the distribution of current use of these methods observed among women Veterans at risk for unintended pregnancy 
in the Examining Contraceptive Use and Unmet Need Among Women Veterans (ECUUN) study.93,117 
g Indicates the probability that newborn care is paid for by VA among women whose pregnancy care is covered by 
VA. 
h Indicates the maximum amount of time that can be covered by OCPs if a woman misses at least 7 days between a 
single refill in a time horizon of twelve 28-day time periods (336 days). 
 
 
Veteran copayments represent negative intermediate costs (i.e. profit) to VA and were 
fixed in the model at –$24 per 3-month supply, or –$96 for a 12-month supply, based on copayment 
rates for 2017.134 Copayments were scaled as above in 3-month arms based on OCP coverage time. 
Whether a Veteran is subject to copayments for medications, including contraceptive methods, is 
based on a variety of factors including income level, military service timeframe and service-
connected disability level.89,134 The proportion of women subject to OCP copayments (35%) was 
determined using FY2017 administrative data. Copayment amounts were multiplied by the 
proportion of Veterans with copayments.  
Outcome costs include the average costs incurred by VA for live births and miscarriages. 
Abortion cost is set at $0, because VA does not cover pregnancy termination under any 
circumstances.135 Live birth costs include prenatal care, intrapartum and delivery care, and 
newborn care, which VA covers for a maximum of 7 days. VA does not provide pregnancy or 
newborn care directly, but contracts with non-VA entities to reimburse this care using VA 
benefits.77 Costs of intrapartum care, newborn care and miscarriage management represent VA 
average payments in FY2015, the latest available data from which we could derive reliable 
estimates. Costs associated with prenatal care are drawn from average costs paid by commercial 
insurers for prenatal care in 2010.132 All costs are presented in 2017 US dollars, with costs from 
prior years inflated using the US Consumer Price Index. 
A proportion of VA enrollees use non-VA insurance benefits (e.g. private insurance or 
Medicaid) to cover pregnancy care. Our base case of 52% of pregnancies paid for by VA was 
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derived from unpublished data from the Examining Contraceptive Use and Unmet Need among 
women Veterans (ECUUN) study,93 where 52% of Veterans currently receiving OCPs from VA 
have no additional, non-VA insurance coverage. Administrative data indicates that VA paid for 
newborn care for approximately 58% of infants born to women whose maternity care was covered 
by VA in FY2015. 
3.2.4  Estimating the number of unintended pregnancies associated with each dispensing 
strategy 
Unintended pregnancy frequency per 1000 women per year associated with each strategy 
was calculated based on the proportion of the cohort experiencing a pregnancy outcome (live birth, 
miscarriage, or abortion) over the model time horizon. We estimated the expected total unintended 
pregnancy frequency by multiplying the frequency per 1000 women per year by the number of VA 
enrollees using OCPs (n=24,309). 
3.2.5  Sensitivity analyses 
We performed one-way sensitivity analyses, independently varying model parameters 
across the ranges shown in Table 6, to identify parameters with the greatest effect on base case 
results. Cost ranges are based on empirical VA data; ranges for probabilities and other parameters 
are based on the literature and are intentionally broad to reflect uncertainty and allow consideration 
of potentially extreme values.136 A tornado diagram was generated to graphically represent one-
way sensitivity analyses, and threshold values (i.e. parameter values at which favored strategies 
change) were determined. 
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To assess overall model robustness and further estimate the effects of parameter 
uncertainty, probabilistic sensitivity analysis with 5000 iterations was performed, simultaneously 
varying all model parameters across plausible distributions.136 Per established guidelines, beta and 
gamma distributions were chosen to approximate probability distributions and right-skewed cost 
data, respectively.136 Table 6 shows distribution means and standard deviations. Standard 
deviations for cost parameters are from VA data; resulting distributions were compared with 
empirical data to ensure reasonable approximation. Standard deviations for other parameters were 
selected to approximate broad but plausible ranges similar to those used in one-way sensitivity 
analyses. We calculated the likelihood that the 12-month option resulted in a lower per-woman 
cost compared to the 3-month strategy, and the 95% probability range of incremental cost 
differences between strategies. 
3.3 Results 
3.3.1  Base case analyses 
Average annual cost per woman was $700.60 for the 12-month dispensing option, 
compared with $787.72 for the 3-month dispensing strategy, resulting in incremental VA cost 
savings of $87.12 per woman per year with the 12-month option. Among the 24,309 women 
receiving OCPs in VA, the 12-month dispensing option is expected to save $2,117,800 annually. 
Cost savings with 12-month dispensing result primarily from reductions in unintended 
pregnancies. Annually, 149 unintended pregnancies per 1,000 women were expected with the 12-
month option, compared to 173 per 1,000 women with the 3-month strategy, for an absolute 
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reduction of 24 unintended pregnancies per 1,000 women per year. This reduction translates to 
583 unintended pregnancies averted annually among women receiving OCPs in VA with adoption 
of a 12-month dispensing option. 
3.3.2  Sensitivity analyses 
One-way sensitivity analyses are shown in Figure 3. Cost savings with 12-month 
dispensing were sensitive to changes at the extremes of plausible ranges for probability of OCP 
coverage gaps with 3-month dispensing, pregnancy risk during gaps, and the proportion of 
pregnancies paid for by VA. Threshold values for these parameters are shown in Table 7.  
In probabilistic sensitivity analysis simultaneously varying each parameter across a 
plausible distribution, the 12-month strategy was cost saving in 95.4% of model iterations. The 
95% probability range of the incremental cost difference ranged from annual cost savings of 
$389.79 per woman to additional costs of $13.34 per woman with the 12-month option compared 
with 3-month dispensing. 
 
 
 45 
 
Figure 3 One-way sensitivity analyses 
Abbreviations: OCP, oral contraceptive pill; p, probability; mo, month; VA, Veterans Affairs 
Bar colors denote the directionality of the parameter range associated with the resultant incremental cost (i.e. dark 
blue bars represent decreasing and light blue bars indicate increasing parameter values relative to the base case).  
a Variation can result in result in the 3-month strategy being favored over the 12-month option. Threshold values are 
reported in Table 7. 
Figure reproduced with permission from JAMA Internal Medicine. 2019. Published online July 08, 2019. 
doi:10.1001/jamainternmed.2019.1678. Copyright©2019 American Medical Association. All rights reserved. 
 
 
 
 
 
Table 7 Threshold values from one-way sensitivity analyses 
Parameter Threshold value a 
Probability VA pays for pregnancy outcome < 0.037 
Probability of ≥ 1 OCP coverage gap given 3 months of OCPs dispensed < 0.031 
Probability of pregnancy during OCP coverage gap(s) b < 0.133 
 
Abbreviations: VA, Veterans Affairs; OCP, oral contraceptive pill 
a 3-month dispensing is less costly than 12-month dispensing at the indicated parameter range. 
b Annual probability of pregnancy given no contraceptive use, which is assumed during OCP coverage gaps (base 
case, 0.85). The overall probability of pregnancy over the model time horizon is prorated according to time using 
OCPs vs. coverage gaps. Annual pregnancy probabilities are also prorated in the model to account for a time horizon 
of twelve 28-day periods (336 days) instead of a full calendar year. 
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3.4 Discussion 
Adoption of a 12-month OCP dispensing option is expected to produce substantial cost 
savings for the VA healthcare system while reducing unintended pregnancies experienced by 
women Veterans. Model results are robust to variations across broad but plausible parameter 
ranges, suggesting that 12-month OCP dispensing is economically feasible for VA while better 
meeting the reproductive needs of the women VA serves. 
The potential consequences of an adverse event (i.e. unintended pregnancy) resulting from 
short gaps in contraceptive coverage are arguably greater than for other prescription medications, 
and pregnancy is a costly outcome for both women and insurers. Although VA uses innovative 
strategies such as a centralized mail-order pharmacy used for nearly 80% of prescriptions, refills 
are not automatic or instantaneous, and potential coverage gaps remain; this is evidenced by the 
43% of women Veterans who experience at least 1 gap between contraceptive refills,125 similar to 
patterns observed in US populations.123,124,126 In this model, sensitivity analyses indicate that only 
3% of women can incur a coverage gap for 3-month dispensing to be favored, an implausibly low 
value based on empirical evidence. In contrast, robust evidence now highlights the potential for 
reduced contraceptive gaps and improved reproductive outcomes with dispensing of greater 
quantities of contraceptives,75,76,126,127 while additional healthcare system contacts have little effect 
on continuation of contraceptive use or patient safety.137,138 In addition to influencing national and 
international medical guidelines,116,128 these data have spurred recent US state-level legislative 
efforts, with 17 states and the District of Columbia requiring coverage of 12-month contraceptive 
supplies as of January 2019.74 As the largest US integrated healthcare system, and with its 
centralized pharmacy, VA is uniquely positioned to implement similar evidence-based policy 
change on a national scale. 
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The substantial incremental cost savings predicted by our model with a 12-month OCP 
dispensing option are in alignment with existing empirical evidence and other models of 
contraceptive cost-effectiveness126,139,140 and, in fact, are intentionally conservative due to multiple 
assumptions biasing against the 12-month strategy. Our model’s projected 14% reduction in 
unintended pregnancy for 12-month versus 3-month dispensing is notably less than the empirically 
observed 30% reduced odds of pregnancy among California family planning program clients,76 
suggesting that real-world implications of this policy change may be greater than our model 
estimates. Despite our conservative assumptions, probabilistic sensitivity analysis indicates that 
12-month dispensing is nearly always cost saving, and that additional costs per woman are minimal 
in rare iterations in which 3-month dispensing is favored. This robustness of model results to 
variations over generous ranges suggests that the projected cost savings with 12-month dispensing 
may translate to other US healthcare contexts, despite potential differences in baseline costs or 
population characteristics. 
Allowing for 12-month OCP dispensing is one mechanism to enhance contraceptive access 
for both US women and women Veterans; however, other policies also limit Veterans’ receipt of 
optimal reproductive health care. First, unlike most insured US women, who have zero cost-
sharing for contraception under the Affordable Care Act,71 some VA enrollees incur copayments 
for contraception, including 35% of women who filled VA OCP prescriptions in FY2017. 
Copayments are associated with reduced contraceptive adherence among women Veterans across 
all income levels109 and may be a barrier to use. In addition, VA policy excludes all abortion 
coverage. While Veterans seek abortion at rates similar to women in the general population,94 VA 
policy is more restrictive than many public insurance programs and the Department of Defense, 
which allow for coverage in cases of rape, incest, or life endangerment.141 Although our model 
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defines abortion as a $0 cost to VA, it clearly represents a nonzero cost to Veterans seeking 
termination of unintended pregnancies. 
Although our results suggest financial benefits to VA of a 12-month OCP dispensing 
policy, it is vital that contraceptive policies serve first and foremost to augment women’s 
reproductive outcomes and autonomy. Economic arguments in family planning have historically 
been used to promote racist and classist policies by positing that limiting the reproduction of poor 
women and women of color can curb societal poverty. Such poverty amelioration arguments have 
led to coercive sterilization programs targeting socially marginalized populations and proposals 
conditioning receipt of welfare benefits on Norplant provision, among other injustices.39,40 Thus, 
although the favorable bottom line suggested by our results may be helpful in influencing policy 
change in VA and other settings, we highlight these potential financial gains as a secondary benefit 
to the more important and evidence-based goal of improving contraceptive access and facilitating 
women Veterans’ individual abilities to manage their reproductive lives as they see fit.  
There are limitations to our work. First, our model does not allow for switching to 
additional prescription contraceptive methods over the 1-year time horizon or account for resultant 
pill wastage, which is a common counterargument against extended medication dispensing. 
However, prescription method switching and pill wastage were low in two large-scale studies in 
Veteran and non-Veteran populations.125,126 In addition, intermediate costs of additional methods 
would likely be negligible compared to cost savings due to reduced unintended pregnancies, as 
seen in empirical data.126 Second, our model may overestimate pregnancy risk by assuming use of 
only non-prescription methods or no contraception among women who discontinue OCPs, and no 
contraception use during OCP coverage gaps. We account for this limitation by broadly varying 
pregnancy probabilities in sensitivity analyses. Results were not sensitive to variations in 
pregnancy probability after discontinuation of OCP use, and annual pregnancy risk given no 
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contraceptive use (assumed during OCP gaps) would have to be less than 13.3% for 3-month 
dispensing to be favored. This value is notably lower than the established annual pregnancy risk 
with no contraception (85%), as well as failure rates for all non-prescription contraceptive methods 
(range 18-28%) that women might use during coverage gaps. Third, our model does not account 
for the possibility that groups of women Veterans choosing 12- versus 3-month OCP supplies may 
differ according to characteristics associated with OCP use, adherence, or risk of unintended 
pregnancy, including medical and mental health comorbidities. Finally, our work is subject to 
inherent limitations of model-based approaches, wherein applicability to real-world situations is 
bounded by assumptions, input data quality and combined parameter uncertainty. To mitigate these 
limitations and produce policy-relevant results, we made structural and parameter assumptions to 
bias against the 12-month dispensing option wherever possible, and varied all parameters 
individually and simultaneously over generous bounds. 
In conclusion, adoption of a 12-month dispensing option for oral contraceptive pills may 
support reproductive autonomy and improve reproductive outcomes for women Veterans, and is 
expected to produce cost savings for VA due to reductions in unintended pregnancies. Thus, the 
proposed policy is expected to be economically feasible for VA while better supporting women 
Veterans in meeting their reproductive goals. 
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4.0 Adherence to Best Practice Guidelines for Provision of Long-Acting Reversible 
Contraception in a Single Large US Healthcare System 
4.1 Introduction 
Use of long-acting reversible contraceptive methods (LARC), including IUDs and 
contraceptive implants, has increased more than 4-fold among US women since the early 
2000s,142,143 likely contributing to recent declines in unintended pregnancy.13 Health care providers 
trained in LARC provision are pivotal to facilitating access to these methods, which are appealing 
to many patients, providers and public health advocates for their high efficacy and low 
maintenance.144 Best practice guidelines for LARC provision, which synthesize existing evidence 
and provide recommendations to maximize access while ensuring patient safety, are maintained 
by the American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease 
Control and Prevention (CDC).116,145 Best practices include same-day LARC provision, placement 
at any point in the menstrual cycle when pregnancy can be reasonably excluded, provision to 
nulliparous and adolescent women, STD screening concurrent with IUD placement, and limiting 
unnecessary follow up. 
Over 90% of obstetrician gynecologists (OBGYNs) provide IUDs and over half provide 
implants,64,146 compared to LARC provision by less than a quarter of family physicians and less 
than 10% of pediatricians.147,148 Prior research suggests substantial variation in knowledge of 
LARC practice guidelines among OBGYNs65,149 and across medical specialties.62,150,151 However, 
there is less research examining specific practices for LARC provision or provider-level adherence 
to best practices, which may impact contraceptive access. We therefore aimed to assess adherence 
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to LARC best practices, particularly same-day LARC provision, among health care providers 
affiliated with a single, large healthcare system in Western Pennsylvania. Specifically, this study 
aimed to describe LARC best practice adherence, characterize provider and practice characteristics 
associated with adherence, and identify provider-reported barriers to best practice implementation 
within a single healthcare system. 
4.2 Methods 
4.2.1  Study design and population 
This study was approved by the institutional review board of the University of Pittsburgh. 
We conducted a web-based, cross-sectional survey with all health care providers affiliated with 
the University of Pittsburgh Medical Center (UPMC) who were associated with at least one 
LARC-related diagnosis, procedure or device code in electronic medical records between October 
1, 2017 and September 30, 2018. Providers currently enrolled in a training program were excluded. 
Provider email addresses were manually sourced using the UPMC email directory; lack of a 
functioning health system email address was assumed to indicate lack of current affiliation with 
the health system. Data cleaning and exclusions resulted in a final recruitment pool of 363 
providers. Additional details regarding recruitment pool creation are provided in Appendix B. 
4.2.2  Recruitment and data collection  
The survey was administered online using University of Pittsburgh licensed Qualtrics 
software (Qualtrics©, Provo, UT). Potentially eligible providers received an email inviting them 
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to participate in the “UPMC LARC Provider Survey” via a personalized link. Participants were 
offered a $10 physical or electronic Starbucks gift card upon survey completion. Participants were 
recruited from December 11, 2018 through January 19, 2019. Three reminder emails were 
distributed to individuals who had not yet completed the survey at approximately 1, 3 and 5 weeks 
after the initial email. An additional message was sent from an OBGYN division chief encouraging 
colleagues to participate. Additional details regarding recruitment are provided in Appendix B. 
4.2.3  Survey development 
We developed a 25-question survey to assess adherence to best practices for LARC 
provision, in accordance with the CDC 2016 US Selected Practice Recommendations (SPR) for 
Contraceptive Use116 and ACOG Practice Bulletin on LARC145 (Appendix C). The survey was 
developed with reference to previously published literature64,152,153 and with iterative input and 
feedback from content experts, including OBGYN family planning specialists. Scenario-based 
questions were used when possible to aid in assessing real-world practice patterns as opposed to 
provider knowledge about best practice guidelines. We pilot tested the survey with 10 residents 
and fellows with relevant experience providing LARC (3 OBGYN residents, 2 OBGYN family 
planning fellows, 2 internal medicine women’s health fellows, and 3 adolescent medicine fellows). 
Pilot participants provided feedback on the online survey format, question wording and response 
options. 
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4.2.4  Measures 
We assessed average monthly frequency of IUD and implant provision over the past 12 
months (none, <1/month, 1-5/month, 6-10/month, >10/month). Participants who had inserted less 
than one or no IUDs or implants per month were asked to select all that apply from a list of potential 
reasons for having placed few or no IUDs/implants, including “other” with an open-ended text 
box. Open-ended “other” responses were recoded to available discrete response options if 
applicable. Providers who reported no provision of a given method during the prior 12 months 
were not asked the remainder of survey questions pertaining to that method. 
Our primary outcome was provision of same-day LARC, which was assessed via two 
questions. Considering their primary practice location, providers were asked to estimate the 
number of office visits experienced by a “typical” patient for IUD or implant placement, from 
deciding she wants the method to having the device placed. Response options were “1 visit,” “2 
visits” or “3 or more visits,” which was dichotomized to 1 visit or 2 or more visits for analysis due 
to low frequency of providers reporting 3 or more visits (n=1 for each method). A second item 
assessed providers’ ability to add a LARC insertion procedure to an annual exam visit at their 
primary practice location, using the following scenario: 
 
Layla is a 26-year-old, established patient of yours. During her scheduled annual exam, 
she tells you she has “done a lot of research” and wants an [IUD/implant] for contraception. 
She has not been sexually active for three weeks and her menstrual period ended 2 days 
ago. Layla is asking if you can insert the [IUD/implant] today. Based on your current 
clinical practice, how likely is it that you can insert the [IUD/implant] during today’s visit? 
 
Response options were “very unlikely,” “unlikely,” “equally likely and unlikely,” “likely” 
and “very likely,” which was dichotomized as “likely/very likely” versus all other responses for 
analysis. Of note, this scenario intentionally describes a patient whom clinicians can clearly be 
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“reasonably certain” is not pregnant per CDC guidelines;116 immediate IUD insertion is therefore 
appropriate. Regardless of the reported likelihood of add-on, participants were then asked to 
identify potential reasons why they might be unable to complete the LARC insertion described in 
the scenario, using a select-all-that-apply question including “other” with an open-ended text box. 
Open-ended “other” responses were recoded to available discrete response options if applicable.  
Other best practice outcomes are based on the CDC SPR and include provision of IUDs to 
nulliparous women (recommended); LARC provision to women under 18 years of age 
(recommended); parental consent requirements for women under 18 (not required under 
Pennsylvania law154); timing of IUD insertion in relation to STD screening (recommendation: 
screen but do not delay insertion; treat with IUD in place); timing of IUD insertion within the 
menstrual cycle (recommendation: insert at any time if reasonably certain not pregnant), use of 
misoprostol for IUD insertion (not recommended), and scheduling of routine follow-up after IUD 
insertion (not recommended).116 We additionally assessed routine stocking of IUDs and implants 
at primary practice locations. 
We collected demographic information including provider type (physician, nurse 
practitioner, physician assistant or midwife), primary medical specialty (OBGYN, family 
medicine, internal medicine or pediatrics), years in practice, gender, and whether the provider 
spends any time practicing in a federally qualified health center (FQHC), Title X or public health 
clinic. Practice-related characteristics include whether the provider’s primary practice is located 
in an academic setting (specified as involved in the training of medical students, residents or other 
health professions trainees), the location of the primary practice (Allegheny County, the location 
of the health system’s main academic medical center and educational programs, versus all other 
counties), and the average number of patients seen per week. All variables were assessed via self-
report on the survey instrument. 
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4.2.5  Data analysis 
Descriptive statistics were generated for all variables and to describe demographic 
characteristics of our study sample. Bivariate associations between provider and practice 
characteristics and same-day provision and other outcomes were tested using Chi-square or Fisher 
exact tests if expected counts were less than n=5. We used multivariable logistic regression to 
identify characteristics associated with same-day LARC outcomes (typical single visit and high 
add-on ability) while adjusting for all variables associated with these outcomes in bivariate 
analyses at the p<0.2 level. Due to prohibitively small sample sizes, participants reporting a 
medical specialty of internal medicine or pediatrics were excluded from analyses examining 
provider specialty as an independent variable. We calculated frequencies of reasons for no/low 
LARC provision and inability to add-on, as well as the number of reasons selected by each 
participant. The relationship between number of potential barriers to LARC add-on and likelihood 
of LARC add-on was assessed using the Jonckheere-Terpstra test for ordered alternatives. All 
analyses were conducted using Stata 14.2 (StataCorp, College Station, TX). 
4.3 Results 
4.3.1  Study population 
Of 363 providers contacted via email, 167 consented to participation in the survey (46%). 
Ten were ineligible (6%), and 4 did not complete the entire survey, for a total of 153 completed 
surveys (response rate 42%) (Figure 4). The majority of respondents were physicians (n=103, 
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67%), and reported a primary medical specialty of OBGYN (n=104, 68%) (Table 8). All advanced 
practice providers (APPs) reported working in OBGYN specialties except for one family medicine 
physician assistant. Participants varied with respect to practice settings, years in practice and 
number of patients seen per week, and 80% were female. 
 
 
 
 
Figure 4 UPMC LARC Provider Survey – Recruitment flow diagram 
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Table 8 Sample characteristics of UPMC-affiliated LARC providers 
Characteristic n (%) a 
Provider Type  
    Physician (MD or DO) 103 (67) 
    Advanced Practice Provider 50 (33) 
         Nurse Practitioner 19 (12) 
         Certified Nurse Midwife 16 (10) 
         Physician Assistant 15 (10) 
Primary Medical Specialty  
    Obstetrics and Gynecology 104 (68) 
    Family Medicine 40 (26) 
    Internal Medicine 5 (3) 
    Pediatrics 4 (3) 
Gender  
    Female 122 (80) 
    Male 31 (20) 
Years in Practice  
    0-4 years 35 (23) 
    5-9 years 32 (21) 
    10-14 years 24 (16) 
    15-19 years 16 (10) 
    20 years or more 46 (30) 
Patients seen per week  
    1-10 12 (8) 
    11-50 50 (33) 
    51-100 78 (51) 
    >100 13 (9) 
Any time practicing in FQHC, Title X 
or public health clinic  
    Yes  24 (16) 
    No 129 (84) 
Primary practice in academic setting  
    Yes 121 (79) 
    No/Unsure 32 (21) 
County of primary practice b  
    Allegheny County 92 (61) 
    Any other county 58 (39) 
 
Abbreviations: FQHC, federally qualified health center 
a N=153. Percentages may not add to 100% due to rounding. 
b Missing data for county of primary practice (n=3). Allegheny County is the location of the health system’s main 
academic medical center and educational programs. 
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4.3.2  Frequency of LARC provision and reasons for low or no provision 
The majority of providers reported placing an average of 1-5 IUDs and implants per month 
(Figure 5a). Ten participants (7%) reported providing no IUDs and 23 (15%) provided no implants 
over the past 12 months. Reasons for no or low provision are shown in Figure 5b, and include few 
or no patients requesting LARC, insufficient training, and another provider in the practice 
responsible for LARC provision. 
4.3.3  Same-day LARC provision 
4.3.3.1 Typical number of visits to obtain LARC 
A single visit to obtain LARC was reported as typical by 37% of IUD providers (n=53/143) 
and 51% of implant providers (n=66/130) (Table 9). For both methods, a typical single visit was 
associated with OBGYN specialty compared to family medicine (IUD: 44% vs. 12%, respectively, 
p=0.001; Implant: 57% vs. 26%, p=0.002) and practicing in Allegheny County versus any other 
county (IUD: 48% vs. 20%, p=0.001; Implant: 65% vs. 27%, p<0.001). For IUDs, a typical single 
visit was additionally associated with seeing fewer patients per week (p=0.02). In multivariable 
models, OBGYN specialty and practicing in Allegheny County remained significantly positively 
associated with reporting a typical single visit for both LARC methods (Table 9). 
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Figure 5 Frequency of LARC provision and reasons for low/no provision 
Panel a) shows the average number of IUDs and implants inserted per month over the past year. Participants who 
placed less than 1 or no IUDs/implants per month selected all that apply from a list of potential reasons for placing 
few or no IUDs/implants.  
Panel b) shows the percentage of respondents selecting each reason for no/low provision, with “other” responses 
recoded as discrete options if applicable. Discrete response options are shown in quotations. Responses labeled 
“Other:” are summarized based on open-ended responses. Responses are not mutually exclusive. 
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Table 9 Associations of provider characteristics with same-day LARC: Typical single visit 
 Single Visit is Typical for LARC Provision 
  IUD (n=143) Implant (n=130) 
Characteristic % p- value a aOR (95% CI)
 b % p- value a aOR (95% CI)
 b 
Total 37 - - 51 - - 
Provider Type  0.25   0.29  
   Physician 40  - 54  - 
   Advanced Practice Provider 31  - 44  - 
Primary Medical Specialty c  0.001   0.002  
   Obstetrics and Gynecology 44  7.94 (2.17, 29.06) 57  4.77 (1.83, 12.46) 
   Family Medicine 12  Ref 26  Ref 
Gender  0.66   0.74  
   Female 36  - 50  - 
   Male 41  - 54  - 
Years in Practice  0.80   0.61  
   0-4 years 39  - 45  - 
   5-9 years 33  - 59  - 
   10-14 years 43  - 59  - 
   15-19 years 25  - 38  - 
   20 years or more 40  - 51  - 
Patients seen per week  0.02   0.36  
   1-10 64  Ref 73  - 
   11-50 49  1.13 (0.24, 5.36) 54  - 
   51-100 27  0.47 (0.10, 2.12) 45  - 
   >100 31  0.78 (0.11, 5.48) 56  - 
Any time practicing in FQHC, 
Title X or public health clinic  0.38   0.75 
 
   Yes  45  - 48  - 
   No 36  - 51  - 
Primary practice in academic 
setting 
 0.30   0.11  
   Yes 39  - 54  1.20 (0.44, 3.23) 
   No/Unsure 29  - 37  Ref 
County of primary practice d  0.001   <0.001  
   Allegheny 48  3.06 (1.29, 7.28) 65  4.68 (1.96, 11.17) 
   All others 20  Ref 27  Ref 
 
Abbreviations: FQHC, federally qualified health center 
Bolded cells indicate statistically significant results. 
a p-values are from Chi-square tests, or Fisher’s exact tests if expected number <5. 
b Logistic regression model with outcome of single visit typical vs. 2 or more visits for IUD or implant provision. 
n=133 for IUD model and n=119 for implant model due to missing data and exclusions. Models are adjusted for the 
variables shown based on associations with the outcome in bivariate analysis at the p<0.2 level. 
c Due to prohibitively small sample sizes, participants reporting a medical specialty of internal medicine (n=5) or 
pediatrics (n=4) were excluded from analyses examining provider specialty as an independent variable. 
d Missing data for county (n=3).  
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4.3.3.2 Ability to add LARC to an annual exam 
In the scenario-based question regarding ability to add LARC insertion to an annual exam, 
48% of IUD providers (n=68/143) and 51% of implant providers (n=66/130) reported it was either 
“likely” or “very likely” they could place the LARC method during the appointment (Table 10). 
High likelihood of add-on ability was associated with OBGYN specialty compared to family 
medicine (IUD: 56% vs. 18%, p<0.001; Implant: 59% vs. 20%, p<0.001) and practicing in 
Allegheny County versus any other county (IUD: 55% vs. 35%, p=0.02; Implant: 61% vs. 33%, 
p=0.002). For implants, high likelihood of add-on ability was additionally associated with the 
provider’s primary practice being located in an academic as compared to a non-academic setting 
(56% vs. 30%, p=0.01). In multivariable models, only OBGYN specialty remained associated with 
high likelihood of add-on ability for both IUDs and implants (Table 10). 
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Table 10 Associations of provider characteristics with same day LARC: Add-on ability 
 Provider is Likely/Very Likely Able to Add LARC to Annual Exam 
  IUD (n=143) Implant (n=130) 
Characteristic % p- value a aOR (95% CI)
 b % p- value a aOR (95% CI)
 b 
Total 48 - - 51 - - 
Provider Type  0.34   0.23  
   Physician 45  - 47  - 
   Advanced Practice Provider 53  - 59  - 
Primary Medical Specialty c  <0.001   <0.001  
   Obstetrics and Gynecology 56  7.89 (2.66, 23.37) 59  7.27 (2.58, 20.47) 
   Family Medicine 18  Ref 20  Ref 
Gender  0.72   0.93  
   Female 48  - 51  - 
   Male 44  - 50  - 
Years in Practice  0.09   0.18  
   0-4 years 58  Ref 61  Ref 
   5-9 years 63  1.37 (0.39, 4.86) 62  0.91 (0.26, 3.24) 
   10-14 years 43  0.39 (0.11, 1.34) 47  0.41 (0.10, 1.74) 
   15-19 years 38  0.79 (0.20, 3.18) 31  0.58 (0.14, 2.47) 
   20 years or more 35  0.32 (0.10, 0.99) 43  0.46 (0.14, 1.53) 
Patients seen per week  0.18   0.20  
   1-10 64  Ref 73  Ref 
   11-50 58  1.47 (0.30, 7.21) 59  0.64 (0.11, 3.86) 
   51-100 41  0.79 (0.17, 3.69) 43  0.51 (0.09, 2.81) 
   >100 38  1.17 (0.16, 8.44) 44  0.53 (0.06, 4.91) 
Any time practicing in FQHC, 
Title X or public health clinic  0.48   0.87  
   Yes  55  - 52  - 
   No 46  - 50  - 
Primary practice in academic 
setting  0.05   0.01 
 
   Yes 52  2.13 (0.79, 5.70) 56  2.41 (0.82, 7.13) 
   No/Unsure 32  Ref 30  Ref 
County of primary practice d  0.02   0.002  
   Allegheny 55  1.77 (0.75, 4.17) 61  2.19 (0.88, 5.43) 
   All others 35  Ref 33  Ref 
 
Abbreviations: FQHC, federally qualified health center 
Bolded cells indicate statistically significant results. 
a p-values are from Chi-square tests, or Fisher’s exact tests if expected number <5. 
b Logistic regression model with outcome of likely/very likely able to add [IUD or implant] to annual exam vs. very 
unlikely, unlikely, or equally likely and unlikely. n=133 for IUD model and n=119 for implant model due to missing 
data and exclusions. Models are adjusted for the variables shown based on significant associations with the outcome 
in bivariate analysis at the p<0.2 level. 
c Due to prohibitively small sample sizes, participants reporting a medical specialty of internal medicine (n=5) or 
pediatrics (n=4) were excluded from analyses examining provider specialty as an independent variable. 
d Missing data for county (n=3).  
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Reasons for potential inability to add a LARC insertion to an annual exam visit are shown 
in Figure 6, and include scheduling/clinic flow issues, needing time to ensure LARC is covered by 
the patient’s insurance, insufficient time for education, counseling or consent, and needing to order 
the LARC device. Only 13% of IUD providers and 12% of implant providers cited no potential 
barriers to LARC add-on. The number of potential barriers cited was inversely associated with 
add-on ability (p-for-trend <0.001 for both IUDs and implants), i.e. the greater the number of 
barriers reported, the lower the reported likelihood of add-on ability. 
 
 
 
Figure 6 Reasons for potential inability to add LARC insertion to an annual exam 
Participants were asked to select all reasons they might be unable to add an IUD or implant insertion to the annual 
exam scenario, considering their primary clinical practice location. Data are percentage of respondents selecting each 
reason among providers of IUDs (n=143) and implants (n=130). Responses were not mutually exclusive with the 
exception of “No reason – I am confident I would always be able to insert.”  
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4.3.3.3 Routine stocking of LARC devices 
When asked directly about stocking of LARC devices, 83% of participants who provide 
IUDs (n=118/143) and 78% of participants who provide implants (n=102/130) reported routine 
stocking of the respective device at their primary practice location. Among the 118 participants 
who reported routine stocking of IUDs, specific device availability was as follows: Mirena 100%; 
ParaGard 93%; Skyla 73%; Kyleena 63%; Liletta 18%. 
 
4.3.4  Adherence to other LARC best practices 
4.3.4.1 LARC for nulliparous women and women under 18 years of age 
All participants reported providing IUDs to nulliparous women, except four who reported 
providing contraception only in the postpartum setting (1 OBGYN physician and 3 OBGYN 
APPs). Nearly all participants reported providing LARC to women under 18 years of age (96% of 
IUD providers; 98% of implant providers); those that did not provide to minors reported seeing 
few or no non-adult patients (data not shown). Among participants who provide LARC to patients 
under 18 years of age, 12% (n=17/137) reported requiring parental consent for IUDs, and 15% 
(n=19/128) for implants. For IUDs, parental consent requirements were less prevalent among 
providers practicing in academic settings (8% vs. 26% non-academic setting providers, p=0.01). 
No providers who spend any time practicing in an FQHC, Title X or public health clinic reported 
requiring parental consent for LARC (IUDs: 0% vs. 15% all other providers, p=0.07; Implants: 
0% vs. 18% all other providers, p=0.04). 
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4.3.4.2 Timing of IUD insertion with STD testing  
When asked about the timing of IUD insertion with routine STD screening for a 23 year-
old patient with three new sexual partners in the past year, 79% of IUD providers (n=113/143) 
reported they would perform STD screening concurrent with IUD insertion, i.e. without delaying 
insertion; 17% (n=25/143) would collect the STD screen and schedule a separate visit for IUD 
insertion once results have returned, and 2% (n=3/143) said they would counsel the patient that 
she is not an appropriate candidate for IUD use based on her sexual partner history. 
4.3.4.3 Timing of IUD insertion within the menstrual cycle 
Among IUD providers, 90% (n=128/143) reported placing IUDs at any time during the 
menstrual cycle if they are confident the patient is not pregnant; 7 (5%) place IUDs during the first 
half of the cycle only, and 8 (6%) place IUDs during menstruation only. Among the 8 providers 
who insert IUDs during menstruation only, all reported they find it easier to insert IUDs during 
menstruation, and 6 reported they require active menstruation to ensure the patient is not pregnant. 
4.3.4.4 Use of misoprostol for IUD insertion  
Among IUD providers, 35% (n=50/143) reported having used misoprostol to assist with an 
IUD insertion in the prior 12 months. Any use of misoprostol was more prevalent among APPs 
(47% vs. 29% of physicians, p=0.03), among individuals working in OBGYN specialties (47% vs. 
6% of family medicine providers, p<0.001), and among providers working in non-academic 
compared to academic settings (52% vs. 30%, respectively, p=0.028). Use of misoprostol was less 
prevalent among providers who spend any time practicing in an FQHC, Title X or public health 
clinic (9% vs. 40% among providers with no time in these settings, p=0.006). 
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Routine use of misoprostol (half of the time or more) was most commonly reported for 
patients with a prior failed IUD insertion (62% of misoprostol users, n=31/50), while 42% of 
misoprostol users (n=21/50) reported routine use for first attempt insertions in nulliparous women, 
and 6% (n=3/50) reported routine use for first attempt insertions in parous women. 
4.3.4.5 Routine follow-up after IUD insertion  
Among IUD providers, 73% (n=104/143) routinely schedule follow-up appointments after 
IUD insertion. OBGYN providers were less likely to schedule routine follow-up compared to 
family medicine providers (67% vs. 88%, p=0.02), as were providers practicing in Allegheny 
County (67% vs. 84% other counties, p=0.03) or academic settings (68% vs. 90% in non-academic 
settings, p=0.01). 
4.4 Discussion 
In our sample of LARC providers within a single, large, academic healthcare system, fewer 
than half reported typical same-day LARC provision or high ability to add LARC to an annual 
exam, while adherence to other best practices was higher. Barriers to same-day provision were 
largely structural or logistical in nature, suggesting substantial room for improving LARC access 
via practice- or system-level interventions. 
This study adds to the literature by examining specific LARC practices and adherence to 
best practice guidelines among physician and advanced practice LARC providers. While two-visit 
insertion protocols are an established barrier to LARC access,155-157 same-day LARC provision 
remains uncommon, despite best practice guidelines. A recent national survey of OBGYN 
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physicians found that only 29% offer same-day IUD placement.146 In our study sample, 44% of 
providers working in OBGYN specialties reported that a single visit is typical for IUDs, and 57% 
for implants, suggesting that providers in our health system may be more adherent to this best 
practice than are providers nationwide. Family medicine providers were significantly less likely to 
offer same-day LARC compared to OBGYN specialists, suggesting that OBGYN physicians and 
women’s health APPs may be more aware of current guidelines for LARC provision than are other 
providers, as noted in prior studies,62,150 or that OBGYN practices are more adept at offering this 
service. Same-day provision was also associated with practicing in Allegheny County, the location 
of our system’s flagship academic medical center and educational programs. This may reflect 
increased awareness of guidelines, or proximity to efforts by departmental leadership and our 
hospital-owned health plan to increase LARC access, as compared to providers practicing in 
satellite locations. Regardless of differences across provider and practice characteristics, our 
results indicate that same-day LARC access is not the norm for the majority of patients in our 
health system. 
Approximately half of providers reported a high likelihood of being able to add a LARC 
insertion to an annual exam. However, only 12-13% were confident they would always be able to 
complete the insertion, and an increasing number of potential barriers was strongly associated with 
reduced likelihood of add-on ability. Practice- and system-level interventions emerge as potential 
solutions to many of the provider-identified barriers to same-day LARC provision identified in our 
study, which were largely logistical. First, same-visit LARC provision is only possible if devices 
are stocked and available on site, which was not the case at the primary practice location of 20% 
of providers in our survey. Practices should be encouraged to purchase devices directly and bill 
for LARC as a medical benefit (i.e. a buy and bill approach), rather than covering LARC methods 
as a pharmacy benefit, in which individual insurance plans are billed to order devices as they are 
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requested. The Family Planning National Training Center (FPNTC), an organization supported by 
the US Department of Health and Human Services Office of Population Affairs, maintains a toolkit 
for same-visit contraceptive provision based on the experiences of family planning experts and 
Title X clinics.158 This toolkit includes a calculator for practices to forecast method demand, 
information about distributor discount programs and other approaches to obtain devices at reduced 
cost to help enable stocking. In addition to distributing such resources, direct incentivization of 
device stocking by the health system, for example by absorbing the cost of unused devices, would 
go a long way to improve access to these methods.  
Many participants were concerned about inadequate appointment durations and potential 
clinic flow disruption with added LARC provision. Some practices mitigate this barrier by 
routinely asking female patients of reproductive age if they wish to discuss contraception or are 
considering LARC when making an appointment, in order to schedule additional time for visits 
requiring more extensive counseling or potential procedures. The FPNTC toolkit recommends 
maintaining pre-made kits of materials needed for LARC insertions to reduce time needed for 
LARC procedures, and suggests performing a time study to evaluate the true impact of same-visit 
contraceptive provision.158  
In addition to time for insertion procedures, nearly half of providers reported time needed 
to ensure insurance coverage as a barrier to LARC add-on. Some practices adept at same-day 
provision designate an administrative employee to verify insurance coverage during appointments. 
If this is not possible, signs in the waiting room could encourage interested patients to verify 
coverage prior to their appointment. Furthermore, because provisions of the Affordable Care Act 
mandate contraceptive coverage without cost sharing for the majority of insured US women,71,72 
the health system could help reduce the need for universal verification by maintaining a list of 
insurers with exceptions to this coverage (e.g. employers with religious affiliations). For those 
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patients who do lack insurance coverage for IUDs, Liletta provides a lower-cost alternative; 
however, this option was the least available in our system, compared to near universal availability 
of Mirena and Paragard among practices stocking IUDs. Finally, approximately 10% of providers 
reported needing a second visit to bill for both the annual exam and the LARC procedure, 
suggesting that some providers are unaware of the option to add a procedure code to an evaluation 
and management (E/M) service code. ACOG maintains a coding guide as part of its LARC 
Program,159 which could be distributed to providers system-wide to correct this common 
misconception and preclude the need for an additional visit. 
Adherence to best practices related to LARC eligibility criteria was substantially greater 
than for indicators of same-day provision, suggesting that efforts to improve provider knowledge 
about LARC eligibility may not be enough to improve access to these methods. Nearly all 
providers reported placing IUDs at any time during the menstrual cycle if they are confident a 
patient is not pregnant, with only 6% requiring patients to be menstruating for IUD insertion. 
Likewise, when reporting barriers to the LARC add-on scenario, less than 5% of providers cited 
inappropriate concerns about pregnancy risk or responded that the patient needed to return during 
menses for insertion. With regards to STD screening, nearly 80% of our sample appropriately 
indicated they would perform routine STD screening concurrent with IUD insertion. Although 
17.5% reported they would schedule a separate visit for insertion following result return, it is 
difficult to interpret this result independently from stocking barriers and other reasons for not 
providing same-day insertions, such as inappropriate concerns about pregnancy. Encouragingly, 
nearly all respondents provide IUDs to nulliparous women and adolescents, and none reported 
eligibility concerns for these populations. However, greater than 10% of providers cited 
inappropriate parental consent requirements for adolescents requesting LARC. The state of 
Pennsylvania allows minors over the age of 14 to provide consent for contraceptive services 
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without parental notification or consent;154 this practice therefore represents an unnecessary, 
provider-created barrier to LARC access for adolescent women. Education around this topic, 
particularly for providers in the community who may be less familiar with legal statutes or see 
fewer adolescent patients, could help to improve availability of the confidential contraceptive 
services that adolescent women deserve. 
Scheduling of routine follow up visits after IUD insertion was reported by greater than 70% 
of providers, and nearly 90% of family medicine providers. Follow-up visits are recommended by 
IUD manufactures and typically include a “string check” examination to ensure proper placement, 
in addition to assessment of satisfaction and side effects. However, additional health system 
interactions following contraceptive provision have not been shown to increase method 
continuation or detection of adverse events,137,138 and best practice guidelines specifically 
recommend against routine follow up, instead advocating for follow up as necessary or during 
“other routine visits.”116 Unnecessary follow up visits create additional burdens of time for 
patients, often require copayments, are poorly attended,160 and may contribute to clinic flow issues 
and long provider wait times. Instead, all patients should be encouraged to follow-up with 
questions or concerns as necessary, potentially via phone or electronic communication to 
determine the need for an in-person visit; education of providers and practice managers regarding 
appropriate follow up may help to reduce this barrier. 
While not directly related to method access, we also identified potentially inappropriate 
use of misoprostol, a prostaglandin E1 analogue used to induce cervical softening and dilation,161 
among IUD providers in our system. CDC guidelines specifically recommend against routine use 
of misoprostol prior to IUD insertions,116 citing high quality evidence that misoprostol use does 
not improve the ease or success of IUD insertions, but may increase patient pain and side 
effects.162,163 Misoprostol may be useful among women with a previously failed insertion,164,165 a 
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patient type cited by the majority of misoprostol users. However, 42% of misoprostol users (15% 
of all IUD providers) also reported routine use of misoprostol for first attempt insertions in 
nulliparous women, suggesting that inappropriate use of misoprostol is fairly common in our 
health system, as noted in other studies.166 Routine use of misoprostol for IUD insertions is 
concerning given the substantial side effects of this medication (including nausea, vomiting, 
diarrhea, cramping and bleeding), which may worsen patient experiences with IUD insertion 
without meaningful benefit. Education should be targeted to practices or providers routinely using 
misoprostol, perhaps in conjunction with additional insertion training to reduce the perceived need 
for a cervical ripening agent. 
Strengths of this study include our ability to compare LARC practices across provider and 
practice characteristics within a single large healthcare system. Key barriers to best practice 
implementation identified by this study will help inform interventions to improve access to LARC 
methods across this system. While our findings are not immediately generalizable to other 
healthcare systems, our sample does comprise multiple types of providers working in different 
specialties and practice settings. Results of this study, and particularly the provider-identified 
barriers to same-day LARC provision, may therefore be applicable to efforts to improve access to 
LARC in other systems. 
Our study has several limitations. First, our study is limited by potential selection bias, as 
providers who chose to complete the survey may be more interested or active in LARC provision, 
and therefore more likely to be adherent to best practices. This could have contributed to 
overestimation of best practice adherence across our healthcare system, and may account for the 
higher rates of same-day provision observed in our study compared to national estimates.64,146 
Desirability bias may also have influenced participants’ reporting of their practice patterns to align 
with knowledge of established guidelines, as opposed to how they actually practice. We attempted 
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to minimize this possibility by using scenario-based questions, maintaining participant 
confidentiality and identifying this research as a student project rather than an assessment by the 
health system. Next, the bulk of respondents were OBGYN physicians and APPs working in 
OBGYN specialties, with more limited representation from primary care providers, who may have 
different experiences providing LARC and face unique barriers. However, our sample is likely 
reflective of the population providing LARC within our system. Although provider practices are 
likely influenced by practice-wide policies and logistics, we are unable to account for clustering 
of providers by practice location. Finally, our study does not examine provider practices related to 
LARC removal, an overlooked component of access for these methods which is vital to protect 
patients’ bodily and reproductive autonomy. 
In conclusion, adherence to established best practice guidelines for LARC provision is 
mixed among providers in a single large healthcare system, with substantial room for improvement 
in same-day LARC provision. Barriers to best practice implementation identified in this study may 
be useful to inform practice- and system-level interventions to improve access to LARC. 
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5.0 Conclusions 
The ability to prevent and time pregnancies through the use of contraception is vital to the 
health, well-being and autonomy of US women. The research presented in this dissertation aimed 
to advance understanding of factors at the patient, provider and system levels that influence 
contraceptive access and use, particularly among the understudied and growing population of 
women Veterans who use VA for health care. Our findings contribute to efforts within the field of 
family planning to develop new measures of contraceptive access rooted in patient preferences, 
and to ongoing endeavors to improve access to contraceptive methods in the VA and UPMC 
healthcare systems. 
In the first paper, we examined contraceptive preference matching among a population of 
women Veterans at risk of unintended pregnancy who have uniform coverage of contraceptive 
methods through VA care. This work represents an important step in the development of more 
patient-centered measures of contraceptive access based on the meeting of patient preferences.22,26 
Similar to prior efforts to examine contraceptive preference matching, our quantitative measure of 
“ideal” contraceptive methods was limited by variable interpretation of an ambiguous question 
stem.103,104 Nevertheless, our findings of high rates of ideal-current method mismatch and 
particularly of reduced match among non-white women and women with mental illness are 
important, and highlight the potential of a more rigorous measure of preference-use agreement to 
serve as a meaningful indicator of disparities in contraceptive access. Future work could focus on 
development and testing of a measure that more clearly defines a preferred or “ideal” method as 
the single method that women most want to be using at the present time within the context of their 
lives, which could then be compared with current use. Better understanding of the reasons that 
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women do not use the methods they feel are best for them at a given time is necessary to inform 
public health initiatives and clinical counseling. However, our qualitative results also emphasize 
the complexity of contraceptive decision-making, such as conflict between preferred method 
features and desire to prevent pregnancy, and of measuring the relative strengths of different 
preferences. Measuring women’s perceived ability to use the contraceptive methods that they most 
want to be using, rather than assessing actual use of a stated preferred method, may be another 
way to gauge access via a slightly different construct. 
This study also identified several modifiable barriers to women Veterans’ use of their stated 
ideal methods, including patient misconceptions about VA contraceptive coverage and provider-
level barriers resulting from knowledge gaps and potential biases. These findings emphasize the 
ongoing need to promote contraceptive education for VA providers, as well as use of patient-
centered counseling strategies which elicit and center patient preferences.21,167 Efforts are ongoing 
in VA to improve awareness of women’s health services, and innovations such as the MyPath 
decision support tool are being evaluated as a method to improve Veterans’ contraceptive 
knowledge and ensure receipt of quality contraceptive counseling in VA primary care.168 
In the second paper, we used decision modeling to translate existing administrative and 
research data and produce real-world estimates of the expected impacts to VA of a 12-month 
contraceptive dispensing policy. We found that offering 12-month OCP supplies would better 
enable women Veterans using OCPs to prevent unintended pregnancies, while also being 
economically sustainable for the healthcare system. The population of women Veterans using VA 
for health care carries a high burden of medical and mental health comorbidities, which may 
increase the vulnerability of this population to pregnancy-related morbidity and other negative 
consequences related to unintended pregnancy.77,81 This medical vulnerability, coupled with zero 
coverage for abortion through VA135 and increasing abortion restrictions across the country,169 
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underscores the importance of enacting strategies in VA that can help women Veterans prevent 
pregnancy when that is their goal. The results of our analysis suggest that extended dispensing is 
a win-win solution for helping women Veterans achieve their reproductive goals while reducing 
VA health system costs, and are in line with emerging empirical data suggesting economic benefits 
related to such policies.170 Our hope is that these results will be considered to inform policy change 
for contraceptive dispensing in VA.  
Were an extended dispensing policy to be adopted in VA, we could use administrative data 
to empirically evaluate the assumptions used to construct our model. For instance, we could assess 
whether sociodemographic characteristics are truly similar between cohorts of women who choose 
to receive 12-months upfront versus shorter supplies, and evaluate differences in refill patterns and 
gaps according to initial dispensing quantities. We could also examine pregnancy occurrence and 
associated costs according to initial dispensing quantities; however, it would be difficult to assess 
the context of pregnancies using administrative data, i.e. whether they were intended, or resulted 
from gaps in contraceptive coverage or contraceptive failure. Furthermore, not all pregnancies 
experienced by women Veterans are expected to be represented in VA data, for example because 
many Veterans have additional insurance coverage and seek pregnancy care in other settings. As 
abortion care is never covered by VA, pregnancies ending in abortion (the outcome of 42% of 
unintended pregnancies among US women) are also unlikely to appear in VA records. Thus, in 
addition to examining administrative data, prospective survey research with longitudinal follow-
up would be necessary to fully evaluate the impact of extended contraceptive dispensing on 
Veterans’ ability to prevent unintended pregnancies. The anticipated difficulty of empirical 
assessment is one reason that modeling is a useful approach for estimating the impacts of this 
proposed policy. Sensitivity analyses suggest that our model’s predictions of favorable 
reproductive and financial outcomes are robust to wide variations in parameter values, which 
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bolsters our conclusion that extended dispensing is an economically sustainable strategy to 
improve women Veterans’ access to hormonal contraception.  
Finally, in the third paper, we examined provider-level adherence to best practice 
recommendations for provision of IUDs and implants across the UPMC healthcare system. We 
found that same-day availability of LARC methods is suboptimal within this system, and that 
adherence to best practice guidelines varies across provider specialties and practice characteristics, 
with OBGYN providers and those practicing in geographic proximity to the main academic 
medical center being more likely to provide same-day access. Providers in our study were 
generally adherent to best practices related to LARC eligibility criteria, such as provision to 
nulliparous women and women under 18, but reported a number of logistical barriers related to 
same-day LARC provision. These barriers aligned with larger problems in healthcare such as 
physician workloads and short appointment times, but also included challenges specific to LARC 
provision, such as device stocking and billing concerns. The results of this study can be used 
inform efforts to improve LARC access within UPMC. Our findings have already been shared 
with OBGYN departmental leadership and incorporated into provider education initiatives for 
providers in non-academic settings. As a next stage, educational initiatives for practice managers 
may be helpful with regards to implementing practice-level solutions regarding stocking, staffing, 
billing, and scheduling of insertion and return visits. Sharing results with the UPMC hospital-
owned health plan may inspire additional system-level interventions. 
There are several future directions for research on LARC best practice implementation. 
First, our survey could be re-administered to UPMC providers in the future, after resource sharing 
and ongoing educational initiatives have reached the majority of providers. This would enable us 
to compare adherence to best practices and availability of same-day provision over time with these 
strategies. Administration of a similar survey to a national sample of LARC providers would be 
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useful to understand specific LARC practices and best practice adherence more broadly, and to 
establish national norms against which individual providers and institutions could evaluate their 
practices. Within UPMC, a standardized set of best practice recommendations could be developed, 
and implementation research approaches used to assess whether interventions such as single-visit 
billing, buy and bill stocking strategies, or maintaining of insertion kits are being incorporated by 
providers and practices, as well as the impact of these strategies on LARC provision. 
5.1 Clinical implications 
Helping women obtain and use contraceptive methods in alignment with their goals and 
preferences is a vital component of preventive health care for women. The research presented in 
this dissertation was performed with the aim of better understanding women’s access to 
contraceptive methods, and furthering that access via evaluation of provider- and system-level 
practices and policies. Our assessment of “ideal” versus current contraceptive use contributes to a 
growing body of literature highlighting the importance of patient preferences and features other 
than efficacy in the selection and use of contraceptive methods. These results can be used in 
support of the development and dissemination of contraceptive counseling strategies which elicit 
and center patient preferences for contraceptive features in addition to reproductive goals.21,167 The 
two other projects in this dissertation contribute valuable evidence to inform practical efforts to 
expand access to specific prescription contraceptive methods within the VA and UPMC healthcare 
systems. Together, the results of this research have the potential to directly impact women’s ability 
to obtain and use contraception, and to improve their experiences in interacting with providers and 
the healthcare system while doing so. 
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Appendix A Women Veterans’ Ideal Method Type According to Sample Characteristics 
Table 11 Women Veterans' ideal method type according to sample characteristics 
 Stated Ideal Method Type (%)  
Characteristic Tubal ligation 
Partner 
vasectomy LARC 
a Hormonal b Non-Rx/ None c 
p-
value d 
Total 14 19 27 25 15 - 
Patient-level       
Age      <0.001 
   20-29 4 12 37 27 21  
   30-34 12 20 27 30 10  
   35-39 21 17 24 20 19  
   40-45 18 30 17 23 12  
Race      0.01 
   Non-Hispanic white 13 19 28 28 12  
   Non-white 14 20 25 23 20  
Marital Status      <0.001 
   Single, never married 6 10 30 28 27  
   Married or Cohabitating 16 24 25 24 12  
   Formerly Married 13 13 29 27 18  
Education       <0.001 
   Less than a bachelor’s degree 13 14 27 28 18  
   Bachelor's degree or higher 14 24 26 23 12  
Annual household income      <0.001 
   < $20,000 11 9 32 27 21  
   $20,000-$59,999 15 16 27 28 15  
   >= $60,000 13 32 24 21 11  
Parity      <0.001 
   Nulliparous  6 12 28 36 19  
   Parous (≥1 live birth) 17 22 26 21 14  
Body Mass Index      0.03 
   Underweight/Normal (<25) 10 18 24 31 17  
   Overweight (25 to <30) 14 21 28 25 13  
   Obese (≥ 30) 17 19 28 20 15  
Medical Illness      0.10 
   Yes 16 20 26 23 15  
   No   11 19 27 28 16  
Mental Illness      0.02 
   Yes 15 21 28 23 14  
   No 11 17 25 30 17  
History of Military Sexual Trauma      0.90 
   Yes 13 20 27 26 14  
   No 14 19 26 25 16  
Ever Deployed      0.03 
   Yes 11 17 29 26 17  
   No 16 22 24 24 14  
Has additional (non-VA) Insurance      0.01 
   Yes 14 24 28 24 13  
   No 13 16 25 27 18  
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Table 11 (continued)       
 Stated Ideal Method Type (%)  
Characteristic Tubal ligation 
Partner 
vasectomy LARC 
a Hormonal b Non-Rx/ None c 
p-
value d 
Provider-level       
VA PCP is female       0.25 
   Yes 14 20 26 26 14  
   No 13 18 27 23 20  
Sees VA PCP for almost all care      0.23 
   Yes 13 18 26 27 16  
   No 15 24 25 21 14  
Sees VA PCP for gynecologic care      0.75 
   Yes 15 20 26 26 15  
   No 13 19 28 24 17  
System-level       
Primary Care at VA WHC      0.68 
   No WHC or don’t know 14 19 26 27 14  
   Yes WHC, not seen there 16 18 29 21 17  
   Yes WHC and seen there 12 20 26 27 15  
On-site gynecologist      0.94 
   Yes 14 19 27 25 15  
   No/Don’t know 13 20 26 26 16  
Census Region      0.29 
   Northeast 11 12 28 37 12  
   Midwest 14 24 22 26 14  
   South 14 19 26 25 15  
   West 13 19 30 21 18  
 
Abbreviations: VA, Veterans Affairs; PCP, primary care provider; WHC, women’s health clinic.  
Data are row percentages. Percentages may not add to 100% due to rounding. 
a Long-acting reversible contraceptive methods, including intrauterine devices and contraceptive implants. 
b Pill, patch, ring, Depo-Provera injections. 
c Non-prescription methods include female or male condoms, withdrawal, natural family planning/fertility awareness-
based methods, spermicides, sponge, and emergency contraception. 
d p-values are from chi-square tests, or Fisher exact tests if expected values were less than n=5. 
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Appendix B UPMC LARC Provider Survey – Recruitment Methods 
B.1 Recruitment pool creation  
The Health Record Research Request (R3) service of the University of Pittsburgh’s 
Department of Biomedical Informatics was used to create a recruitment pool of potentially eligible 
health care providers for the UPMC LARC Provider Survey. R3 provides researchers with access 
to data from the Neptune Research Data Warehouse, which compiles and standardizes electronic 
medical record data from various sources across the UPMC health system on a monthly basis.171 
R3 performed a search to identify all health care providers associated with at least one LARC-
related diagnosis, procedure and device code between October 1, 2017 and September 30, 2018 
(Table 12).  
Provider name, credentials (MD, DO, CRNP, CNM or PA), medical specialty, and 
National Provider Identifier (NPI) were provided; no patient data was collected. The initial search 
by R3 resulted in 629 potentially eligible participants (Figure 7). Our recruitment pool was reduced 
to 405 providers following exclusion of current trainees (n=94); two OBGYN physicians who were 
closely involved in survey development; a neurology CRNP with a single code for IUD removal 
and insertion, which was presumed to be a coding error; and individuals associated only with CPT 
codes 11981 and/or 11983 (insertion and/or removal of a non-biodegradable drug delivery 
implant) and working in specialties unlikely to provide contraception (e.g. anesthesiology, non-
OBGYN surgical specialties, podiatry) (n=127). Use of these non-specific CPT codes by these 
providers was assumed to indicate alternative applications. Email addresses were then manually 
sourced using the UPMC email directory. Emails were not found or were undeliverable for 42 
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individuals, of whom 33 (79%) were confirmed via NPI and/or internet searches to have left the 
UPMC healthcare system; for the 9 providers not confirmed to have left the system, lack of a 
functioning health system email address was assumed to indicate lack of current affiliation with 
UPMC. These exclusions resulted in a final recruitment pool of 363 providers. 
 
 
 
Table 12 UPMC LARC Provider Survey – diagnosis, procedure and device codes used to identify potentially 
eligible providers 
Code Definition 
Diagnosis Codes – International Classification of Diseases, 10th revision, Clinical Modification 
   Z30.014  Encounter for initial prescription of intrauterine contraceptive device 
   Z30.017 a Encounter for initial prescription of implantable subdermal contraceptive  
   Z30.430  Encounter for insertion of intrauterine contraceptive device  
   Z30.433 Encounter for removal and reinsertion of intrauterine contraceptive device 
Procedure Codes – Current Procedural Technology (CPT) 
   58300 Intrauterine contraceptive device insertion 
   11981 b Insertion, non-biodegradable drug delivery implant 
   11983 b Removal with reinsertion, non-biodegradable drug delivery implant 
Device Codes – Healthcare Common Procedure Coding System (HCPCS) 
   J7296 Levonorgestrel-releasing intrauterine contraceptive system (Kyleena), 19.5 mg 
   J7297 Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 5-year duration 
   J7298 Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 5-year duration 
   J7300 Intrauterine copper contraceptive 
   J7301 Levonorgestrel-releasing intrauterine contraceptive system, 13.5 mg 
   J7307 Etonogestrel (contraceptive) implant system, including implant and supplies 
 
a Z30.017 was not found in electronic medical records within the time frame queried. 
b These codes are not specific to contraceptive implants. Providers who were only associated with one or both of these 
codes and with medical specialties unlikely to prescribe contraception were excluded from the recruitment pool 
(n=127). 
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Figure 7 UPMC LARC Provider Survey – Recruitment pool creation 
B.2 Recruitment 
Providers on our recruitment list were sent a recruitment letter via their UPMC email 
address inviting them to participate in the “UPMC LARC Provider Survey” (Figure 8). Emails 
contained a personalized URL link to the survey, to allow for response tracking and targeting of 
reminder emails to non-responders. The survey was hosted on pitt.co1.qualtrics.com, using 
Qualtrics software (Qualtrics©, Provo, UT) licensed to the University of Pittsburgh. Participants 
were recruited from December 11, 2018 through January 19, 2019, with reminder emails sent to 
individuals who had not yet completed the survey on December 18, January 2, and January 14. A 
message from an OBGYN division chief encouraging colleagues to participate was also sent on 
January 14. 
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Participants were offered a $10 Starbucks gift card upon survey completion as a token of 
appreciation. Participants could elect to receive the gift card electronically at an email address of 
their choosing or via US Mail to a provided address; they could also decline to receive a gift card. 
Among 153 participants who completed the survey and were therefore eligible for compensation, 
100 (65%) selected an electronic gift card, 36 (24%) selected a physical gift card, and 17 (11%) 
declined compensation. 
 
Figure 8 UPMC LARC Provider Survey – Sample recruitment email  
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Appendix C UPMC LARC Provider Survey – Survey Instrument 
Screening questions: (bold = answer necessary for survey participation) 
1. Are you a health care provider currently affiliated with The University of Pittsburgh 
Medical Center (UPMC)?  
a. Yes / No 
2. Are you currently completing a clinical training program (e.g. professional school, 
residency, or fellowship)? 
a. Yes / No 
3. Have you, or a trainee under your direct supervision, inserted at least 1 intrauterine 
device (IUD) or 1 contraceptive implant in the past 12 months? 
a. Yes / No 
 
 If eligible, continue to survey. If not eligible, thank for time and exit survey.  
 
Intrauterine Devices 
1. Over the past 12 months, how many intrauterine devices (IUDs) have you placed per 
month, on average? Please include IUDs inserted by trainees under your direct supervision. 
 
a. No IUDs in past 12 months 
b. <1 IUD per month 
c. 1-5 IUDs per month 
d. 6-10 IUDs per month 
e. ≥10 IUDs per month 
 
If none (a) or <1/month (b), 
1a) What are the reasons you have placed few or no IUDs in the past year? (select all 
that apply) 
 
a. I feel I do not have sufficient training to provide IUDs 
b. Placing IUDs is generally outside the scope of my practice 
c. Few or none of my patients have requested IUDs 
d. Few or none of my patients are appropriate candidates for IUDs 
e. I receive inadequate reimbursement for providing IUDs 
f. It is too expensive to provide IUDs within my clinical practice 
g. It is too logistically challenging to provide IUDs within my clinical practice 
h. There is another provider within my practice that is primarily responsible for 
IUD provision 
i. Other (specify): __________ 
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1b) If a patient expresses interest in an IUD, is there a specific colleague you refer 
them to?  
 
a. Yes, to a colleague inside of my primary clinical practice 
b. Yes, to a colleague outside of my primary clinical practice 
c. No, I do not typically refer patients for IUDs 
d. N/A – I have not had a patient express interest in an IUD 
 
None (a)  skip to Implants 
<1/month (b)  continue to Q2 
 
 
2. Consider the following scenario in the context of your primary clinical practice 
location:  
Abbi is a 23-year-old woman who calls your office asking to set up an appointment for 
IUD insertion. She is a new patient. How would your office respond to Abbi’s request? 
My office would:  
 
a. schedule Abbi for an initial appointment for contraceptive counseling, to be 
followed by a return visit specifically for IUD placement if medically appropriate 
and desired 
b. schedule Abbi for a single appointment for counseling and potential IUD 
insertion, if medically appropriate and desired 
c. Other (specify): _________ 
 
3. Consider the following scenario in the context of your primary clinical practice 
location:  
Layla is a 26-year-old, established patient of yours. During her scheduled annual exam, 
she tells you she has “done a lot of research” and wants an IUD for contraception. She 
has not been sexually active for three weeks and her menstrual period ended 2 days ago. 
Layla is asking if you can insert the IUD today. Based on your current clinical practice, 
how likely is it that you can insert the IUD during today’s visit? 
 
a. Very unlikely that I can insert the IUD today 
b. Unlikely that I can insert the IUD today 
c. Equally likely and unlikely 
d. Likely that I can insert the IUD today 
e. Very likely that I can insert the IUD today 
 
3a) Considering your primary clinical practice location, which of the following are 
reasons why you might be unable to place an IUD for Layla during this visit? (select 
all that apply) 
 
a. None of the reasons below – I am confident I would always be able to insert 
the IUD in the above scenario 
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b. Scheduling/clinic flow – I may not have time to add the procedure to today’s 
appointment 
c. Insufficient time for patient education, method counseling and/or consent 
d. Staffing issue (e.g. unavailability of an assistant) 
e. My office does not routinely stock IUDs; need time to order 
f. My office needs time to ensure that the IUD will be covered by the patient’s 
insurance (pre-authorization) 
g. My office needs to schedule a second visit to be able to bill for both the 
annual exam and the IUD placement procedure 
h. The patient needs to return during her menstrual cycle for IUD insertion 
i. I need to have results of an STD screen prior to IUD insertion 
j. I need to have results of a Pap test prior to IUD insertion 
k. I do not have enough evidence to rule out pregnancy at this time 
l. Other (specify): _________ 
 
4. Consider the following scenario in the context of your primary clinical practice 
location:  
Deena is a 23-year-old woman presenting for an annual exam and IUD insertion. She is 
currently using Depo-Provera for birth control, and her last dose was 2 months ago. She 
reports 3 new sexual partners in the past year. Per CDC guidelines, you recommend 
routine STD screening. Based on your current practice, which of the following would 
you do with regards to STD screening and IUD insertion? 
 
a. Collect STD screen and insert the IUD today (i.e. in the same visit) 
b. Collect STD screen and schedule the insertion for after the test results have 
returned 
c. Counsel Deena that she is not an appropriate candidate for an IUD based on her 
sexual partner history 
d. Other (specify): _________ 
 
5. In your estimation, how many office visits does your typical patient have for IUD 
placement (i.e. from deciding she wants an IUD to having the device placed)? Please 
consider your primary clinical practice location.  
 
a. 1 visit  
b. 2 visits 
c. 3 or more visits 
 
6. Does your primary clinical practice location routinely stock IUDs? 
 
a. Yes 
b. No 
c. Unsure 
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If Yes (pop up on same page), 
6a) Which of the following IUDs does your primary clinical practice routinely stock? 
(select all that apply) 
 
a. ParaGard (copper IUD) 
b. Mirena (52 mg levonorgestrel) 
c. Liletta (52 mg levonorgestrel) 
d. Kyleena (19.5 mg levonorgestrel) 
e. Skyla (13.5 mg levonorgestrel) 
f. Other (specify): ________  
 
7. When during a woman’s menstrual cycle do you place an IUD? 
 
a. During menstruation only 
b. During the first half of the menstrual cycle (i.e. before ovulation to assure she is 
not pregnant) 
c. At any time during the menstrual cycle provided I am confident that she is not 
pregnant.    
 
If during menstruation only (a), 
7a) Which of the following explain why you insert IUDs during menstruation only? 
(select all that apply) 
 
a. I find it easier to insert an IUD while the patient is menstruating 
b. I require my patients to be actively menstruating to ensure that they are not 
pregnant 
c. Other (specify): _______ 
 
8. Do you provide IUDs to nulliparous women (i.e. women who have never given birth)? 
a. Yes  
b. No 
 
If no, 
8a) What reasons explain why you do not provide IUDs to nulliparous women? 
(select all that apply) 
 
a. I feel that IUDs are medically inappropriate for nulliparous women 
b. I feel that IUDs are socially or morally inappropriate for nulliparous 
women 
c. I find it more challenging to insert an IUD in nulliparous women 
d. Other (specify): __________ 
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9. Do you provide IUDs to patients under 18 years of age? 
 
a. Yes 
b. Yes, if the patient has previously given birth 
c. No 
 
If yes (a or b) 
9a) Do you require parental consent to place an IUD for women under 18 years of 
age? 
a. Yes 
b.  No 
 
If no (c), 
9b) What reasons explain why you do not provide IUDs to women under 18 years of 
age? (select all that apply) 
 
a. I feel that IUDs are medically inappropriate for adolescents 
b. I feel that IUDs are socially or morally inappropriate for adolescents 
c. I find it more challenging to insert an IUD in adolescent patients 
d. I am concerned about potential medicolegal consequences of providing 
IUDs to patients under 18 
e. Other (specify): _________ 
f. N/A – I do not see any patients under 18 years of age 
 
10. Providers use a variety of methods to help manage patient discomfort during IUD 
insertion. In the past 12 months, how often have you recommended or provided the 
following to your patients for pain management during IUD insertion?  
 
 
 
11. Are you trained to provide a cervical block? 
a. Yes 
b. No 
 
 
Method Never Occasion-ally 
About half 
of the time 
Most of the 
time Always 
OTC painkiller      
Vaginal lidocaine gel       
Cervical block      
Other (specify): ___      
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12. In the past 12 months, have you ever used misoprostol to assist with an IUD insertion? 
a. Yes 
b. No 
 
If yes,  
12a) In the past 12 months, how often have you used misoprostol to assist with IUD 
insertion for the following types of patients? (select all that apply) 
 
 
12b) Please share more about your experience using misoprostol for IUD insertion:  
______________ 
 
13. Do you routinely schedule patients for a return/follow-up visit after IUD insertion (string 
check, ultrasound, etc.)? 
a. Yes, I routinely schedule patients for a return visit after IUD insertion 
b. No, I do not routinely schedule patients for a return visit after IUD insertion 
 
13a) Please describe the reasons you do or do not recommend a routine return visit 
following IUD insertion: ______________ 
 
14. Consider the following scenario: Jesse is a 21-year-old patient with a scheduled 
appointment for IUD removal. Upon talking with her you learn that her Mirena IUD was 
placed 5 months ago. She describes unpredictable light bleeding and says she “just 
doesn’t want it anymore.” Briefly, how would you counsel Jesse and proceed? 
[text box] 
 
 
 
Never Occasionally 
About 
half of 
the time 
Most of 
the time Always 
N/A – I have 
not inserted an 
IUD for this 
type of patient 
Nulliparous 
women (1st 
insertion attempt) 
      
Parous women  
(1st insertion 
attempt) 
      
Women who have 
had a failed IUD 
insertion 
      
Other (specify): 
__________ 
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Contraceptive Implants 
15. Over the past 12 months, how many contraceptive implants (e.g. Nexplanon) have you 
placed per month, on average? Please include implants inserted by trainees under your 
direct supervision. 
a. No implants in past 12 months 
b. <1 implant per month 
c. 1-5 implants per month 
d. 6-10 implants per month 
e. ≥10 implants per month 
 
If none (a) or <1/month (b),  
15a) What are the reasons you have placed few or no contraceptive implants in the 
past year? (select all that apply) 
 
a. I feel I do not have sufficient training to provide contraceptive implants 
b. Placing contraceptive implants is generally outside the scope of my practice 
c. Few or none of my patients have requested contraceptive implants  
d. Few or none of my patients are appropriate candidates for contraceptive 
implants 
e. I receive inadequate reimbursement for providing contraceptive implants 
f. It is too expensive to provide contraceptive implants within my clinical 
practice 
g. It is too logistically challenging to provide contraceptive implants within my 
clinical practice  
h. There is another provider within my practice that is primarily responsible for 
contraceptive implant provision 
i. Other (specify): __________ 
 
15b) If a patient expresses interest in a contraceptive implant, is there a specific 
colleague you refer them to? 
 
a. Yes, to a colleague inside of my primary clinical practice 
b. Yes, to a colleague outside of my primary clinical practice 
c. No, I do not typically refer patients for implants 
d. N/A – I have not had a patient express interest in a contraceptive implant 
 
None (a)  skip to General/end 
<1/month (b)  continue to Q16 
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16. Consider the following scenario in the context of your primary clinical practice 
location:  
A 25-year-old woman named Mikayla calls your office asking to set up an appointment 
for contraceptive implant insertion. She is a new patient. How would your office respond 
to Mikayla’s request? 
My office would:  
 
a. schedule Mikayla for an initial appointment for contraceptive counseling, to be 
followed by a return visit specifically for implant placement if desired and 
medically appropriate 
b. schedule Mikayla for a single appointment for counseling and potential 
placement of the implant, if medically appropriate and desired at that time 
c. Other (specify): _________ 
 
17. Consider the following scenario in the context of your primary clinical practice 
location:  
Carla is a 26-year-old, established patient of yours. During her scheduled annual exam, 
she tells you she has “done a lot of research” and wants “the arm implant” for 
contraception. She has not been sexually active for three weeks and her menstrual period 
ended 2 days ago. Carla is asking if you can insert the implant today. Based on your 
current clinical practice, how likely is it that you can place the implant for Carla during 
today’s visit? 
 
a. Very unlikely that I can place the implant today 
b. Unlikely that I can place the implant today 
c. Equally likely and unlikely  
d. Likely that I can place the implant today 
e. Very likely that I can place the implant today 
 
17a) Considering your primary clinical practice location, which of the following 
reasons explain why you might be unable to place the implant for Carla during this 
visit? (select all that apply) 
 
a. None of the reasons below – I am confident I would always be able to insert 
the implant in the above scenario  
b. Scheduling/clinic flow – I may not have time to add the procedure to today’s 
appointment 
c. Insufficient time for patient education, method counseling and/or consent 
d. Staffing issue (e.g. unavailability of assistant) 
e. My office does not routinely stock contraceptive implants; need time to order 
f. My office needs time to ensure that the implant is covered by the patient’s 
insurance (pre-authorization) 
g. My office needs to schedule a second visit to be able to bill for both the 
annual exam and the implant placement procedure 
h. The patient needs to return during her menstrual cycle for implant insertion 
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i. I need to have results of an STD screen prior to implant insertion 
j. I need to have results of a Pap test prior to implant insertion 
k. I do not have enough evidence to rule out pregnancy at this time 
l. Other (specify): _________ 
 
18. In your estimation, how many office visits does your typical patient have for implant 
placement (i.e. from deciding she wants an implant to having the device placed)? Please 
consider your primary clinical practice location.  
 
a. 1 visit  
b. 2 visits 
c. 3 or more visits 
 
19. Does your primary clinical practice routinely stock contraceptive implants (e.g. 
Nexplanon)? 
 
a. Yes 
b. No 
c. Unsure 
 
20. Do you provide contraceptive implants to patients under 18 years of age?  
 
a. Yes 
b. No  
 
If yes (a), 
20a) Do you require parental consent to place a contraceptive implant for women 
under 18 years of age? 
 
a. Yes 
b.  No 
 
If no (b), 
20b) What reasons explain why you do not provide implants to women under 18 
years of age? (select all that apply) 
 
a. I feel that contraceptive implants are medically inappropriate for 
adolescents 
b. I feel that contraceptive implants are socially or morally inappropriate for 
adolescents 
c. I am concerned about potential medicolegal consequences of providing 
contraceptive implants to patients under 18 
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d. Other (specify): _________ 
e. N/A – I do not see any patients under 18 years of age 
 
21. Consider the following scenario: Alexis is a 21-year-old patient with a scheduled 
appointment for contraceptive implant removal. Upon talking with her you learn that her 
implant was placed 5 months ago. She describes unpredictable light bleeding and says 
she “just doesn’t want it anymore.” Briefly, how would you counsel Alexis and proceed? 
[text box] 
 
General 
22. Consider the following scenario: You obtain a PAP smear from Ava, a 21-year-old 
healthy woman, during a routine annual examination. The PAP smear is normal. When 
do you recommend she undergoes her next PAP smear?  
 
a. Next year 
b. 2 years from now 
c. 3 years from now 
d. 5 years from now 
e. Other: ________ 
f. N/A – I do not perform PAP smears 
 
23. Do you have access to a specific provider or clinic with expertise in IUDs and/or 
implants for referral or consultation, for example in the case of a difficult insertion or 
removal? 
 
a. Yes 
b. No 
c. Unsure 
 
 
 
Open-ended questions 
1. What barriers, if any, exist to IUD and/or contraceptive implant provision at your primary 
practice location? 
[text box] 
 
 
2. What can the health system do to help reduce these barriers? 
[text box] 
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Demographic Questions 
1. What type of provider are you? 
 
a. Physician (MD, DO) 
b. Nurse Practitioner (CRNP, APRN) 
c. Midwife (CNM, CPM, CM) 
d. Physician Assistant (PA) 
e. Other provider type (specify): ________ 
 
1a) What is your primary medical specialty? 
a. Obstetrics and Gynecology 
b. Internal Medicine 
c. Family Medicine 
d. Pediatrics 
e. Other (specify): __________ 
 
If MD/DO: 
1b) Have you completed subspecialty or fellowship training? 
a. Yes  
b. No 
 
If yes,  
1bi) Please specify the type of subspecialty or fellowship training you have 
completed:  
 
[text box] 
 
2. How many years have you been in practice (i.e. following completion of your training)? 
a. 0 – 4 years 
b. 5 – 9 years 
c. 10 – 14 years 
d. 15 – 19 years 
e. 20 years or more 
 
3. Which of the following best describes your primary clinical practice? 
a. Hospital-based clinic 
b. Free-standing/community clinic 
c. Other (specify): _________ 
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4. Is your primary clinical practice located in an academic setting (i.e. involving the 
training of medical students, residents or other health professions trainees)? 
 
a. Yes 
b. No 
c. Unsure 
 
5. Is any portion of your time spent practicing in a federally qualified health center, Title X 
clinic or public health clinic? 
 
a. Yes 
b. No 
 
6. In what state is your primary clinical practice located? 
 
a. Pennsylvania (PA) 
b. Ohio (OH) 
c. Other (specify): ________ 
 
7. In what county is your primary practice location? 
 
[Drop down list of counties depending on which state selected] 
 
8. What is the US Postal Code of your primary practice location? 
 
[Text box with validation for US Postal Code] 
 
9. Approximately how many patients do you see in an average week, including encounters 
in which you are directly supervising a trainee?  
 
a. 1-10 patients/week 
b. 11-50 patients/week 
c. 51-100 patients/week 
d. 101-150 patients/week 
e. More than 150 patients/week 
 
10. Approximately what percentage of your patients are female? 
[Sliding scale for percentages 0-100%, base = 50%] 
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11. Approximately what percentage of your encounters with female patients involve 
contraceptive counseling or contraceptive method provision?  
 
[Sliding scale for percentages 0-100%, base = 0%] 
 
12. Approximately what percentage of your patients are <18 years of age? 
 
[Sliding scale for percentages 0-100%, base = 0%] 
 
 
13. What is your age? 
 
[Drop down list ages 22-95] 
 
14. What is your gender? 
 
a. Female 
b. Male 
c. Transgender male 
d. Transgender female 
e. Non-binary/Gender non-conforming/Genderqueer 
f. Other identity (please specify): ________ 
 
 
Thank you for taking the UPMC LARC Provider Survey! We appreciate your participation. 
Please select "Finish" below to submit your responses. You will be redirected to enter your 
contact information to receive a $10 Starbucks gift card as a token of our appreciation. Thank 
you! 
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